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1. Introduction 
 
1.1. DNA as a tunable adaptor for siRNA polyplex 
stabilization and functionalization 

1.1.1. RNA interference 
 
The first mention of RNA interference was in 1993, when Ambros and co-workers 
discovered that LIN-14 protein downregulation in C. elegans is not mediated by 
proteins [1]. The lin-14 locus was found to code for RNA transcripts complementary 
to short repeats in the 3’ untranslated region (3’ UTR) of the lin-14 mRNA, which 
turned out to be responsible for this phenomenon. With the discovery of other 
regulatory RNAs in C. elegans and various organisms in the early 2000s [2, 3], it 
became apparent that this was not a single case. The effectors were 21- to 23-
nucleotide double-stranded RNAs mediating gene silencing on the mRNA level, 
termed microRNAs. 
In the meantime, it was discovered that introduction of artificial small double-stranded 
RNA (termed siRNA) could mediate knockdown of a gene of interest guided through 
complementary base pairing to the coding mRNA as demonstrated separately by 
Mello [4] and Tuschl [5]. 
Soon after, the catalytic mechanism behind the RNA interference process was 
elucidated. The major effector machinery was the RNA induced silencing complex 
(RISC), consisting of the complementary short RNA and multiple proteins with 
different functions in RNA loading, anchoring and target mRNA processing [6]. 
The discovery of RNA interference opened the door for therapeutic intervention in 
various directions. Artificial introduction of siRNA or microRNA is utilized to regulate 
gene expression on the mRNA level and interference with the endogenous microRNA 
machinery is achieved through antisense approaches.  
 
Despite their different origins, siRNAs and microRNAs have in common that they are 
processed from longer double-strands by the RNase III family endonuclease Dicer 
into 21 to 23 base pairs double-strands, leaving a two nucleotides 3’ overhang and 5’ 
monophosphates (Figure 1) [7]. This active form is loaded into the RISC complex. An 
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Argonaute family protein, which is part of the RISC complex, anchors the 
siRNA/microRNA [8]. The strand with the least thermostable base pairs at the 5’ end 
is selected as guide strand, which directs the RISC complex to the target site through 
complementary base pairing [9]. The passenger strand is removed and either 
degraded or incorporated as a new additional guide strand [10]. For target mRNA 
processing, two cases have to be distinguished. Either the mRNA is cleaved at a 
defined position between nucleotide 10 and 11 counted from the 5’ end of the guide 
strand, followed by exonucleolytic degradation, or the RISC complex remains 
associated to the target mRNA leading to translational repression. Prerequisites for 
the prior case are a perfect sequence match between the guide strand and the target 
mRNA and the presence of Argonaute 2 as part of the RISC complex. Argonaute 2 is 
the only protein of the Argonaute family executing RNase H activity [11]. In any other 
case, gene silencing is accomplished by translational repression. 
 
Differences between siRNA and microRNA can be found in their origin. siRNAs are 
part of the defense mechanism against invasive nucleic acids from viruses, 
transposons or centromeres. Long double-stranded RNA is directly processed by 
Dicer and directed against the nucleic acids from which it is derived. Therefore siRNA 
guide strands are typically perfectly complementary to their target RNA which is 
processed via the Argonaute 2 dependent cleavage mechanism [8]. 
In contrast, microRNAs are endogenous regulatory elements. They are transcribed in 
the nucleus from non-coding regions commonly in clusters of several different 
microRNAs. These so-called pri-microRNAs are further processed by the RNase III 
family protein Drosha to pre-microRNAs, which are hairpin structures including only 
one microRNA [12]. After the protein exportin 5 mediates their translocation to the 
cytosol [13], the mature microRNA is generated by Dicer as described above (Figure 
1). In mammalian cells, microRNAs mediate silencing almost exclusively through 
translational repression. Target sequences lie in the 3’ UTR of the open reading 
frame and have several mismatches for pairing with the microRNA guide strand. A 
perfect match is only required for the seed region which comprises nucleotides 2 to 8 
counted from the 5’ end of the microRNA guide strand [14]. This implies that a single 
microRNA can have several targets and regulates expression of a set of proteins.  
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Figure 1. microRNA/siRNA biogenesis. The pri-microRNA is transcribed in the nucleus and trimmed 
by Drosha to pre-microRNA, which is a hairpin structure including one microRNA. The pre-microRNA 
is transported to the cytosol by exportin 5. This is where the pathway of microRNA and siRNA 
maturation come together. Long double-stranded RNA from exogenous origin (which is the precursor 
of siRNA) and pre-microRNA are both processed to their 21- to 23-base pair mature forms by the 
endonuclease Dicer. After incorporation into the RISC complex, mRNA downregulation is achieved by 
two different mechanisms. In case of a perfect sequence match to the target sequence and the 
presence of endonucleolytically active Argonaute 2 (Ago2) in the RISC complex, the mRNA is cleaved 
at a defined position (siRNA, microRNA in plants). Upon imperfect sequence match or presence of any 
other Argonaute protein (Ago1, Ago3, Ago4), the outcome is translational repression by mRNA 
blockade (microRNAs in mammals). 
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1.1.2. siRNA as a therapeutic tool 
 
At a first glimpse, siRNA seems to be the perfect drug to conquer a huge variety of 
diseases associated with genetic dysregulation. The sequence can be designed 
complementary to any target mRNA, leading to knockdown of a protein of interest 
and interference with any cellular process. Once incorporated into the RISC complex, 
the siRNA guide strand is stable for weeks and able to recognize and cleave multiple 
mRNAs in a catalytic manner. Therefore only a few hundred siRNAs in the cytosol 
are sufficient to provide efficient downregulation of the target [15]. Nevertheless only 
a couple of siRNA based drugs have proceeded to late clinical phases so far. The 
utilization of siRNA as a therapeutic agent faces various obstacles, which are the 
subject of current research. 
First of all, one has to differentiate between local and systemic administration. Local 
administration is less challenging as the delivery to the target tissue is not an issue 
here [16]. This is the reason why the only clinically approved RNA therapeutic is the 
aptamer Macugen against macular degeneration, which inhibits the vascular 
endothelial growth factor in the eye [17]. But as only few target sites like eye, skin or 
lung are accessible by local administration, systemic delivery via intravenous 
injection is required to access a broader spectrum of target tissues. The potential of 
this strategy is demonstrated by a recent boost in RNAi formulations in clinical trials 
targeting various cancers, the liver, the gastrointestinal tract and infectious diseases 
[18]. 
When entering the bloodstream, the siRNA molecule is exposed to a variety of 
molecules and blood cells. Recognition by Toll-like receptors and uptake by 
phagocytes leads to activation of the innate immune system [19, 20] and nucleases 
may rapidly degrade the siRNA. Some of these issues can be addressed by chemical 
modification of the siRNA itself. In addition, the siRNA can be packed into 
nanoparticles and shielded with hydrophilic molecules like polyethylene glycol to 
prevent interaction with the environment (Figure 2a).  
After crossing the endothelial barrier and diffusing through the extracellular matrix, 
the siRNA has to enter the target cell. As both the siRNA and the cell membrane are 
negatively charged, a promising strategy has been to complex the siRNA with 
cationic polymers like polyethylenimine (PEI) to obtain nanopartices with a positive 
surface charge and facilitated interaction (Figure 2b) [21]. One can further include a 
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ligand for a cell-type specific receptor to increase interaction and specificity. Once the 
siRNA has entered the cell through endocytosis, the next hurdle is the release to the 
cytosol, which is its site of action (Figure 2c).  
 


 
 
Figure 2. Barriers in siRNA delivery can be overcome with functionalized cationic oligomers. 
(a) The siRNA is formulated into a nanoparticle. (b) Association and internalization of the polyplex into 
the target cell is facilitated by a positive zeta-potential and cell type-specific receptor binding. (c) 
Endosomal escape can be mediated by the proton sponge effect and membrane interacting peptides 
and fatty acids. (d) Including bioreducible disulfides facilitates dissociation of the siRNA from the 
oligomer. Finally the free siRNA can be incorporated into the RISC complex and exert its function. 
 
Cationic carriers with a high buffer capacity can counteract the acidification of the 
endosome, leading to an increased influx of H+ and Cl- ions. Osmotic pressure 
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increases and the carrier becomes increasingly cationic and membrane-destabilizing. 
The endosome bursts and releases its cargo to the cytosol (proton sponge effect) 
[22, 23]. Membrane destabilizing peptides and membrane interacting fatty acids can 
promote liberation to the cytosol as well [24, 25]. A final step, before the siRNA can 
be incorporated into the RISC complex and guided to the mRNA of interest, is its 
release from the delivery vehicle. The reducing environment of the cytosol can be 
exploited by including disulfides which are stable in the extracellular environment, but 
reduced in the cytosol, leading to destabilization of the nanoparticle (Figure 2d) [26]. 
Even after functionally incorporated into the RISC complex, the siRNA can still exert 
toxicity through off-target effects. Seed region pairing to sequences in distinct 
mRNAs can lead to unwanted translational repression similar to the microRNA 
mechanism. This unspecific knockdown has shown to be reduced by 2’-O-Methyl 
ribose modification of the second nucleotide counted from the guide strand 5’ end 
[27].  
Taking all the above mentioned barriers into account, our working group is designing 
sequence defined carriers based on an oligoethanamino amide core conjugated to 
various functional entities to enable delivery of the siRNA to the target site [28].  
 
1.1.3. Sequence-defined cationic oligomers 
 
Our group has created a library of over 1000 sequence defined cationic oligomers by 
solid phase peptide synthesis (SPPS) to figure out how the abovementioned barriers 
can be overcome by combining functional entities in different ways (Figure 2). The 
core of the oligomers are SPPS-compatible oligoethanamino amide units like Stp 
(succinoyl-tetraethylene pentamine), Sph (succinyl-pentaethylene hexamine) or Gtp 
(glutaryl-tetraethylene pentamine) [29]. These artificial amino acids gain additional 
positive charges upon endosomal protonation. They can be combined to differently 
shaped structures (U-shaped, T-shaped, i-shaped, comb-like, dendrimers) by 
incorporation of branching lysines [30, 31].  
Fatty acids or tyrosines can be included to provide stabilization through hydrophobic 
interaction [32]. Terminal cysteines stabilize the polyplex further in extracellular 
environment through disulfide bridging. Disulfides are reduced in the cytosol and 
promote the release of the siRNA from its carrier [33]. 
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As the positive surface charge of nucleic acid/oligomer nanoparticles might promote 
aggregation with serum proteins, we use hydrophilic molecules like polyethylene 
glycol (PEG) for shielding. Also the particle size can be tuned by selecting PEG 
chains of different length [34]. In general, size is an issue that has to be considered 
carefully. Plain siRNA, for example, would be prone to rapid renal clearance due to 
its small size of only 2 x 7 nm [35]. Too large particles or aggregates however trigger 
toxicity in an in vivo setting. Interaction with the target cell can be facilitated by 
incorporating targeting ligands. Each cell type expresses a characteristic pattern of 
membrane proteins on their surface. A couple of receptors have been identified to be 
highly overexpressed in certain cancer types, representing attractive starting points 
for targeting ligand selection. Folic acid (targeting the folic acid receptor) [36], GE11 
(targeting the EGF-receptor) [37] or transferrin (targeting the transferrin receptor) [38] 
were already successfully incorporated into the oligomers.  
To circumvent endosomal entrapment, our group uses the endosomolytic peptide 
INF7, which is a synthetic analog of the influenza virus N-terminus of the 
hemagglutinin subunit HA-2 that in natural conditions triggers fusion with the 
endosomal membrane [39]. Including histidines increases the buffer capacity of the 
polyplex, promoting the proton sponge effect and the endosome to burst [22]. 
When optimizing the carrier, its nucleic acid cargo has to be taken into account. 
Polyplexes formed with plasmid DNA are generally more stable than those with 
siRNA [40]. The large size and high charge density of plasmid DNA promotes 
formation of robust interelectrolyte complexes, which is a requirement for an efficient 
delivery agent. siRNA is constrained to only 21 to 23 base pairs in its mature form 
and hence less suitable for stable polyplex formation. Therefore, better complexation 
can be achieved by direct modification of the siRNA. With its high charge density, 
good biocompatibility and inexpensive synthesis, DNA is an attractive option to 
extend siRNA for improved polyplex formation [41]. 
 
1.1.4. DNA as building block 
 
In 1982, Seeman could demonstrate that DNA can be used to form structures that 
differ from the conventional linear double-strands by introducing junctions and 
assembling them into lattices [42]. In the following years, the utilization of DNA as a 
building block and not as a carrier of genetic information, has expanded peaking in 
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the invention of the DNA origami strategy in 2006 by Paul W. K. Rothemund [43]. By 
using a long backbone strand and numerous short staple strands, it was possible to 
design and assemble complex three-dimensional structures by Watson Crick base 
pairing. The design of such structures is facilitated by computational tools like 
CADnano [44] for complex DNA origamis or NUpack [45] for small assemblies. At the 
time, the toolbox of DNA nanostructures ranges from simple assemblies such as 
polyhedrons [46-48] up to very complex designs like tubes and boxes using the 
abovementioned DNA origami approach [41, 49, 50]. 
An attractive feature of DNA nanostructures is that functional domains can be placed 
at defined positions with high precision. As high definition is a prerequisite for 
reproducible therapeutic application, DNA is a highly suitable backbone for 
therapeutic cargo delivery. Despite additional favorable properties, like 
biocompatibility and easy synthesis, only a couple of them have been tested in siRNA 
delivery so far [51]. 
 
1.1.5. siRNA extension 
 
The strategy of increasing the charge density of siRNA for better complexation with 
polycations has been pursued in several approaches during the past few years. An 
evident possibility is siRNA multimerization via sticky ends [52] or disulfide chemistry 
[53, 54]. A disadvantage of this strategy is that the number of siRNAs per structure is 
not uniform, which is a serious drawback when defined formulations are required. In 
this respect, the design of defined nanostructures came into focus. This can be 
achieved by utilizing chemical [55] or DNA based backbones, the latter being a key 
aspect of this work. This strategy has already demonstrated to improve transfection 
efficiency for small, medium-sized and large DNA backbones. Even short DNA 
overhangs increased transfection efficiency after complexation with polyethylenimine 
[56]. A few star-shaped structures [57-60] and a folate-targeted DNA tetrahedron 
hybridized to a defined number of siRNAs provided efficient uptake [61]. 
Furthermore, a DNA nanotube, also conjugated to folate, could successfully be 
delivered to folate receptor bearing cells [62]. However none of these studies sets a 
focus on which characteristics of the DNA extension/backbone are really necessary 
to improve delivery. For therapeutic administration, the nanostructure has to be 
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formulated into a drug agent that can be synthesized reproducibly in large scale. It is 
advisable to keep the construct as simple as possible. 
 
 
1.2. Localization and integrity of small single-stranded 
RNA 
 
1.2.1. Single-stranded oligonucleotide therapeutics 
 
Apart from the double-stranded, canonical siRNA and microRNA formats, a huge 
variety of therapeutic approaches exist that utilize single-stranded RNA. Even the 
guide strands of siRNA and microRNA have shown to work without their passenger 
strands. In detail, a 2’-F/2’-O-Me/PS modified single-stranded siRNA guide strand 
was used to efficiently silence mutant Huntingtin allele in a HD model mice [63] (for 
detailed explanation of stabilizing RNA modification see chapter 1.2.3). A 
metabolically stable 5’ phosphate (E-vinylphosphonate) is essential for in vivo activity 
[64]. Also single-stranded microRNA-mimics could guide gene silencing in cells in 
culture [65]. Advantages of the single-stranded format include the smaller size, the 
reduction of off-target effects as no passenger strand has to be co-delivered and the 
possibility to functionally deliver the siRNA without the need for formulation [64, 66]. 
A second class of therapeutic single-stranded RNAs is antisense oligonucleotides 
[67]. The sequences are designed to bind to mRNA at various positions and 
processing stages through complementary base pairing. In that respect, the 
specificity of RNase H for cleavage of RNA/DNA duplexes can be exploited by 
applying DNA strands complementary to the mRNA sequence, which should be 
inactivated [68].  
Furthermore, antisense oligonucleotides can block cellular processes by binding to 
the mRNA. Miss-splicing diseases are especially suitable for antisense mediated 
therapy. Non-functional proteins are produced by wrong assembly of exons during 
splicing. Antisense oligonucleotides can bind to the regions responsible for the 
dysregulation and induce exon skipping or inclusion of exons to restore the correct 
protein variant [69, 70]. While an antisense preparation against Duchenne muscular 
dystrophy failed in clinical phase III [71], studies on spinal muscular atrophy are still 
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ongoing [72, 73]. Additional points for intervention by antisense oligonucleotides 
include inhibition of translation initiation, translational arrest and inhibition of 
polyadenylation by blocking the responsible region in the mRNA [74]. 
When antisense oligonucleotides are used to target microRNAs by complementarity 
to the guide strand, they are called antagomirs [75]. This class of small RNAs has 
been subject to extensive research in the past years. Various different backbone 
modifications have been evaluated for microRNA downregulation efficiency. A 
seminal work form 2006 demonstrates that PS/2’-O-Me modified oligonucleotides can 
be used to silence several microRNAs in mice [76]. Another Interesting approach is 
locked nucleic acid modified oligonucleotides. The oxygen at 2’ and the carbon at 4’ 
position of the ribose are bridged leading to a rigid 3’ endo conformation. Due to their 
high double-strand melting temperature, only a stretch of 8 nucleotides that targets 
the seed region of the microRNA is sufficient to provide its downregulation in vivo 
[77]. A promising candidate for HCV infection therapy in late clinical phases is 
miravirsen. The mir122 targeting 15-nucleotide sequence is composed of DNA 
nucleotides, locked nucleic acids and PS linkages [78]. 
An approach that is not based on complementary base pairing is CpG 
oligodeoxynucleotides. They are single-stranded DNA oligonucleotides containing an 
unmethylated cytosine/guanine motif, which act as immunostimulants through the 
Toll-like receptor 9 [79, 80]. 
 
1.2.2. Unspecific RNases 
 
The cell has developed many pathways for RNA processing and degradation [81]. As 
this work focuses on the fate of single-stranded RNA, our interest is concentrated on 
unspecific ribonucleases (RNases) capable of cleaving single-stranded RNAs in 
mammalian cells. In general, RNases can be divided into three categories, namely 
endonucleases, 3’-5’ exonucleases and 5’-3’ exonucleases. 
The most prominent mammalian endonucleases are part of the RNase A or RNase 
T2 family. The RNase A superfamily comprises RNase 1 to 8, which share a highly 
thermostable disulfide bonded structure, a pH optimum of around 8 and a specificity 
for cleavage of single-stranded RNA 3’ of pyrimidines [82, 83]. RNase T2 family 
members have a broader range of substrates and are able to cleave next to all four 
bases. With a pH optimum of 4-5, they are most active in lyzosomes [84]. 
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Exonucleases either cleave in 3’-5’ or in 5’-3’ direction. The exosome is a multi-
enzyme complex residing in the cytosol and the nucleus, which is responsible for 3’-
5’ degradation. The catalytically active domains are mammalian analogues to the 
bacterial polynucleotide phosphorylase (PNPase) [85]. In the cytoplasm, degradation 
from the 5’-3’ direction can be accomplished in p-bodies. These are small 
cytoplasmic foci containing various enzymes involved in mRNA processing including 
exonuclease Xnr1 [86]. The Xnr1 paralogue Xnr2 is involved in RNA degradation in 
the nucleus [87]. 
 
1.2.3. Chemical modification of RNA 
 
Single-stranded RNA oligonucleotides are especially susceptible to degradation by 
unspecific RNases. Apart from packaging the oligonucleotides into nanoparticles it 
has proven to be highly effective to chemically modify the RNA backbone.  
During the past years a huge variety of internucleotide, sugar and base modifications 
have been developed, that can be implemented to increase stability, binding affinity 
and immunostimulatory properties. In the following, the chemical modifications used 
in this work are discussed in detail. 
As internucleotide modification, phosphorothioate bonds were used instead of 
phosphodiester bonds (Figure 3). Replacing the oxygen with sulfur introduces 
chirality at the phosphate. In R conformation, the linkage is still susceptible to 
nucleolytic degradation. The S conformation however disturbs the active site of the 
nuclease, leading to the increased resistance. Apart from that favorable property, 
phosphorothioates reduce complement binding affinity compared to unmodified RNA 
[88]. Other internucleotide modifications commonly used to counteract nuclease 
susceptibility include N3-phosphoramidate, boranophosphate, morpholino or 
phosphonoacetate modifications [89]. 
Ribose modifications are typically introduced at the 2’ position. 2’-O-Methyl (2’-O-Me) 
and 2’-Fluoro (2’-F) modifications were used in this work (Figure 3). Both keep the 
oligonucleotide in a 3’ endo conformation, mimicking the RNA structure. 2’-F 
modification and to some extent also 2’-O-Me modification have shown to increase 
the binding affinity to their complementary sequence and can therefore be used to 
counteract the detrimental properties of the phosphorothioate linkages [90]. Fluorine 
is highly electronegative leading to an enthalpy driven stabilization of the duplex. The 
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decreased hydration compared to the unmodified form leads to enhanced base 
stacking [91, 92].  
The 2’-O-Me modification provides additional nuclease resistance and reduces 
recognition by the immune system, which to a lesser extent applies to the 2’-F 
modification. Other commonly used ribose modifications include locked nucleic acids 
or 2’-O-(2-methoxyethyl) modification. 
 
 

Figure 3. Chemical backbone modifications used in this work. 2’-O-Me and 2’-F modification 
increases the nuclease resistance and double-strand melting temperature. Phosphorothioate 
modification increases the nuclease resistance. 
 
All chemical modifications discussed above are already part of a FDA approved 
formulation and represent a realistic approach for improving nucleic acid therapy [89]. 
 
1.2.4. Localization and stability of small RNA 
 
Most studies on the impact of chemical modifications on bioactivity of small RNA 
therapeutics rely on quantitative readouts like reporter gene knockdown efficiency [4, 
93] or in case of antagomirs on microRNA target upregulation [94, 95]. Nevertheless, 
sophisticated designs can only be accomplished if the fate of such modified 
oligonucleotides is elucidated after their introduction into the target cell. A few studies 
are available dealing with intracellular stability and localization of chemically modified 
small RNA.  
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An early work compares localization and stability of microinjected phosphodiester 
and phosphorothioate oligonucleotides by fluorescence microscopy. Both show fast 
nuclear translocation. While phosphodiester oligonucleotides were degraded already 
after 20 min, phosphorothioate oligonucleotides displayed stability over 24 h [96]. 
Later on, the formation of nuclear bodies was observed after delivery of 
phosphorothioate modified antisense oligonucleotides by transfection and 
microinjection [97]. 
Another study demonstrates that the rate of false-positives for 2’-O-Me molecular 
beacons can be reduced by including phosphorothioate linkages. Cytosolic retention 
by conjugation to NeutrAvidin also decreases non-specific hairpin opening and 
degradation [98]. Furthermore, the stability of a malachite green aptamer was 
monitored by the increased fluorescence of malachite green after binding [99] and 
the fate of chemically modified antagomirs was elucidated after in vivo delivery, 
indicating a RNAi independent degradation mechanism as the antagomirs do not 
localize in p-bodies [100]. Eventually, the duplex stability and localization of siRNA 
was monitored by Hirsch et al. by intensity based FRET [101]. 
 
1.3. Aims of the thesis 
 
The aim of the first part of the thesis was to provide an overview of how DNA adaptor 
molecules can be used to improve cellular delivery of siRNA in polyplexes with 
sequence defined cationic oligomers. Different aspects of siRNA extension with DNA 
had to be illuminated: 
- multi-siRNA vs. single-siRNA constructs 
- single vs. double-stranded DNA adaptors 
- influence of DNA adaptor length 
- reducible vs. non-reducible adaptor connection 
- siRNA functionalization via DNA adaptors 
- validity of the findings for different transfection agents 
 
The aim of the second part of the thesis was to find a suitable setup for the 
examination of the fate of small RNAs after exposure to cellular environment. Dual-
fluorophore labelled RNA oligonucleotides that differ in their extent of stabilizing 
backbone modifications had to be compared. The degradation rate of those 
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oligonucleotides was to be monitored in cell extracts and the localization dependent 
integrity to be recorded in cells in culture.  
For the cell extract measurements, various ultrasensitive fluorescence methods like 
fluorescence correlation spectroscopy, fluorescence cross-correlation spectroscopy 
and Förster resonance energy transfer should be compared. The methods had to be 
examined with respect to their sensitivity and ability to distinguish unspecific effects 
from RNA degradation. 
Fluorescence lifetime imaging microscopy was to be used to examine the fate of the 
chemically stabilized oligonucleotides when they are transfected with a sequence 
defined cationic carrier. Their localization, integrity and intracellular retention should 
be monitored with this approach.  
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Oligonucleotides 

The following oligonucleotides were purchased from Axolabs (Kulmbach, Germany) 
except the DNA adaptors, which were purchased from Sigma Aldrich (Steinheim, 
Germany) 
Nomenclature: A = 2’-H, A = 2’-OH, a = 2’-O-Me, s = phosphorothioate, fA = 2’-F 
C6SSC6 = symmetrical hexyl disulfide linker   
 
2.1.1.1. eGFP siRNAs 
 
siRNAs targeting the enhanced green fluorescent protein 
 
Guide strand    UGCUUGUCGGCcAUGAuAUTsT  
Passenger strand   AuAucAuGGccGAcAAGcATsT 
SS-passenger strand      (C6SSC6)AuAucAuGGccGAcAAGcATsT 
Passenger strand 5’ extension    GCCGGATCGCCACATAAC-AuAucAuGGccGAcAAGcATsT 
Passenger strand 3’ extension   AuAucAuGGccGAcAAGcATsT-CGACGGATATACATGACG 
 
2.1.1.2. CTRL siRNAs 

siRNAs with a non-functional control sequence 
 
Guide strand     CuAAuAcAGGCcAAuAcAUTsT 
Passenger strand     AuGuAuuGGccuGuAuuAGTsT 
SS-passenger strand    (C6SSC6)AuGuAuuGGccuGuAuuAGTsT 
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2.1.1.3. Modified RNA single-strands 

Stable control    usfCscsfAsusfCsasfUsusfAscscscsgsgsfCsasfGsusfAsusfUsa 
Instable control    UCCAUCAUUACCCGGCAGUAUUA 
Construct 1     usfCscsfAsusfCsasfUsusfAscsCsCGsGsfCsasfGsusfAsusfUsa 
Construct 2     uscscsasUCAUUACCCGGCAGUsasususa 
 
2.1.1.4. DNA extensions/adaptors 

 
 
 
 
 
 
 
 
 
 
  SS-extension 5'   GCCGGACGCCACATAAC (C6SSC6)
  SS-extension 3'   (C6SSC6) CGACGGATATACATGACG
  1bb2si   GTTATGTGGCGATCCGGCACGATAACATCTTAGCTCTGCGCACGCGTTAGTCCCGATAACTCGTCATGTATATCCGTCG
  4bb4si   GTTATGTGGCGATCCGGCACGTAGTGATAAGAATGCTGCGCAGTACTTCGGCTCATAACGGCGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCACGTAGTGATAAGAATGCTGCGGCAGAGCTAAGATGTTATCGGCGTCATGTATATCCGTCG
  CCGATAACATCTTAGCTCTGCGGCAGCATTCTTATCACTACGT
  CCGATAACATCTTAGCTCTGCGGCAGCATTCTTATCACTACGT
  3bb6si   GTTATGTGGCGATCCGGCACGATAACATCTTAGCTCTGCGCACGCGTTAGTCCCGATAACTCGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCTGTTATCGGGACTAACGCGTGAGCAGCATTCTTATCACTACGGCGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCACGTAGTGATAAGAATGCTGCGGCAGAGCTAAGATGTTATCGGCGTCATGTATATCCGTCG
  5bb10si   GTTATGTGGCGATCCGGCACGATAACATCTTAGCTCTGCGCACGCGTTAGTCCCGATAACTCGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCACGTAGTGATAAGAATGCTGCGCAGTACTTCGGCTCATAACGGCGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCTCGTTATGAGCCGAAGTACTGACGCTACTATGGTCATCGTGCACGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCAGCACGATGACCATAGTAGCGAGCAGAGCTAAGATGTTATCGGCGTCATGTATATCCGTCG
  GTTATGTGGCGATCCGGCTGTTATCGGGACTAACGCGTGAGCAGCATTCTTATCACTACGGCGTCATGTATATCCGTCG
  Ext I   CGGCTCATGCGGCAGCTAGCACGTCATGTATATCCGTCG
  Ext II   GCTAGCTGCCGCATGAGCCGTCGACGGAAGTCACGGGAACG
  Ext III   GCACTCGAGGTGATCCATGCCCGTTCCCGTGACTTCCGTCG
  Ext IV   GCATGGATCACCTCGAGTGCACGAGCACGCACATTTCATGC
  Ext V   TCCTCACTTTAACTATCCACTGCATGAAATGTGCGTGCTCG
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2.1.2. Cationic oligomers 
 
Oligomer ID  Structure 
188    C-Stp4-K(PEG24-A)-Stp4-C 
278    C-K(K-LinA2)-Stp3-K(K-LinA2)-C 
356    C-Stp4-K(PEG24-FolA)-Stp4-C 
454    C-Y3-Stp2-K(K-OleA2)-Stp2-Y3-C 
689    C-(H-Stp)3-H-K(H-(Stp-H)3-C)2 
 
C: cysteine; Stp: succinoyl-tetraethylene pentamine; K: lysine; PEG24: polyethylene 
glycol consisting of 24 ethylene glycol units; A: alanine; LinA: linoleic acid; FolA: folic 
acid; Y: tyrosine; OleA: oleic acid; H: histidine. 
 
2.1.3. Reagents 
 
Acetonitrile     VWR Int, Darmstadt, Germany 
Acrylamide/bis-acrylamide, 30%  
solution, 37.5:1    Bio-Rad, Munich, Germany 
Agarose NEEO ultra-quality  Carl Roth, Karlsruhe, Germany 
Ammonium persulfate   Sigma-Aldrich, Steinheim, Germany 
Atto488-NHS ester    Atto-Tec, Siegen, Germany 
Cell culture consumables   NUNC Langenselbold, Germany 
Dimethylsulfoxide    Sigma-Aldrich, Steinheim, Germany 
5,5'-Dithiobis-(2-nitrobenzoic acid)  Sigma-Aldrich, Steinheim, Germany 
Dithiotreithol     Sigma-Aldrich, Steinheim, Germany 
D-luciferin sodium    Promega, Mannheim, Germany 
DMEM     Sigma-Aldrich, Steinheim, Germany 
EDTA      Sigma-Aldrich, Steinheim, Germany 
Ethanol     Sigma-Aldrich, Steinheim, Germany 
Fetal bovine serum    Life Technologies, Darmstadt, Germany 
GelRed 10000x solution   VWR Int, Darmstadt, Germany 
HEPES     Biomol, Hamburg, Germany 
INF7 peptide     Biosyntan, Berlin, Germany 
Isopropanol     Sigma-Aldrich, Steinheim, Germany 
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Magnesium chloride   Sigma-Aldrich, Steinheim, Germany 
MTT      Sigma-Aldrich, Steinheim, Germany 
Paraformaldehyde    Sigma-Aldrich, Steinheim, Germany 
PMSF      Sigma-Aldrich, Steinheim, Germany 
Potassium chloride    Sigma-Aldrich, Steinheim, Germany 
RPMI-1640     Life Technologies, Darmstadt, Germany 
Sodium borate    Sigma-Aldrich, Steinheim, Germany 
Sodium chloride    Sigma-Aldrich, Steinheim, Germany 
Streptomycin    Life Technologies, Darmstadt, Germany 
TEMED     Sigma-Aldrich, Steinheim, Germany 
Tetramethylrhodamine-6-maleimide Life Technologies, Darmstadt, Germany 
Triethylamine    AppliChem, Darmstadt, Germany 
Tris(2-carboxyethyl)phosphine   Sigma-Aldrich, Steinheim, Germany 
Trizma base     Sigma-Aldrich, Steinheim, Germany 
Trypsin/EDTA    Biochrom, Berlin, Germany 
 
2.1.4. Buffers 
 
Buffer A 10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 0.2 mM PMSF,     
0.5 mM DTT, pH 7.9 
Fixation buffer PBS containing 4 % paraformaldehyde 
HBG   20 mM HEPES, 5% glucose, pH 7.4 
HEPES buffer 20 mM HEPES, pH 8.4 
PBS   137 mM NaCl, 2.7 mM KCl, 12 mM phosphate, pH 7.4 
SB buffer  100 mM sodium borate, 20 % Acetonitrile, pH 8.5 
SP buffer  50 mM sodium phosphate, 20 % Acetonitrile, pH 7 
TBE buffer  89 mM Trizma base, 89 mM boric acid, 2 mM EDTA-Na2, pH 8 
TEAA buffer  0.1 M TEAA (from acetic acid, triethylamine), pH 7 
TM buffer  10 mM Tris-Cl, 5 mM MgCl2, pH 7.5 
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2.1.5. Cell lines 
 
HeLa    human cervical carcinoma cells 
KB/eGFPluc human cervical carcinoma cells stably expressing an 
eGFP-luciferase fusion protein 
Neuro2A/eGFPluc murine neuroblastoma cells stably expressing an                    
eGFP-luciferase fusion protein 
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2.2. Methods 
 
2.2.1. Conjugation and assembly of oligonucleotides and DNA 
nanostructures 

2.2.1.1. Assembly of the siRNAs and the DNA nanostructures 

All DNA nanostructures used in this work were designed with NUPACK [45]. The 
constructs were assembled in TM buffer (10 mM Tris-Cl; 5 mM MgCl2, pH 7.5) to 
yield a concentration of 1-6 µM. The components were mixed in their respective 
molar amount, incubated at 95 °C for 5 min and cooled to RT at a rate of ca. 2 
°C/min. The siRNA nanostructures were assembled with the oligonucleotides 
described in the materials part.  
 
2.2.1.2. Coupling of the DNA extensions to the siRNA 
passenger strands with disulfide chemistry 

Disulfide modified siRNA was reduced with buffered tris(2-carboxyethyl)phosphine 
(TCEP, 700 times molar excess, pH 7) for 2.5 h at RT. TCEP was removed by EtOH 
precipitation. The remaining pellet was activated with 2.5 mM 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB, 17 times molar excess) for 1 h at RT. The activated siRNA 
was purified by EtOH precipitation and dissolved in 20 mM HEPES pH 8.4. The 
absence of dimers was verified with native polyacrylamide gel electrophoresis. 
Disulfide modified DNA extensions were reduced with buffered TCEP (700 times 
excess, pH 7), purified by EtOH precipitation and dissolved in HEPES buffer. The 
activated siRNA and the reduced DNA extensions were combined at a concentration 
of 50 µM and incubated at RT for 1h. Reaction was completed upon standard 
freezing to -20 °C, presumably facilitated by the temporarily high concentrations in 
the mother liquor. The products were purified by EtOH precipitation and HPLC. Their 
correct size and purity was verified by native polyacrylamide gel electrophoresis. 
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2.2.1.3. Coupling of DNA extension strands to INF7 

The cysteine of the INF7 peptide (GLFE AIEG FIEN GWEG MIDG WYGC) was 
activated with DTNB (17 times molar excess) and purified by HPLC. The product was 
incubated with the TCEP reduced DNA extension (see chapter 2.2.1.2) in 20 mM 
HEPES pH 8.4 for 1 h at RT and frozen to -20 °C. The product was again purified by 
HPLC and verified by agarose gel electrophoresis.  
 
2.2.1.4. Labelling of the RNA oligonucleotides with Atto488 
and tetramethylrhodamine 

The 3’-amino and 5’-disulfide modified oligonucleotide was dissolved in 100 mM 
sodium borate buffer containing 20 % acetonitrile (pH 8.5) to a final concentration of 
800 µM. Atto488-NHS ester was dissolved in anhydrous DMSO to a working 
concentration of 1 mM. Three molar equivalents of Atto488-NHS ester solution were 
added over 2 h every 15 min, following 3 h incubation at 25 °C. The resulting 
construct was purified by EtOH precipitation and redissolved in water to a 
concentration of 1 mM. The disulfide modified end was reduced with buffered TCEP 
(700 times molar excess, pH 7) for 2.5 h at RT. TCEP was removed by EtOH 
precipitation. The remaining pellet was redissolved in 50 mM sodium phosphate 
buffer 20 % acetonitrile pH 7 to a concentration of 800 µM. Tetramethylrhodamine-6-
maleimide was dissolved in anhydrous DMSO to a working concentration of 1 mM. 
The tetramethylrhodamine-6-maleimide solution (1.3 equivalents) was added 
immediately to the oligonucleotide solution, following incubation of 2 h at 25 °C. The 
product was purified by EtOH precipitation and HPLC. 
 
2.2.1.5. Purification with high performance liquid 
chromatography 

Purification of the dual-labelled RNA oligonucleotide and the DNA extensions 
coupled via a disulfide bond to the siRNA passenger strand or INF7 was performed 
using high performance liquid chromatography (VWR Hitachi Chromaster consisting 
of 5430 Diode array detector and 5160 gradient pump, Darmstadt, Deutschland). The 
products were separated with a XTerra C8 column (5 m, 4.6 x 150 mm, Waters, 
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Eschborn, Germany) and eluted with a 0.1 M triethylammonium acetate/acetonitrile 
gradient (95:5 to 35:65 in 30 min). Product containing fractions were identified by 
their retention, absorbance maxima and by native polyacrylamide gel 
electrophoreses, lyophilized and stored at -20 °C. 
 
2.2.1.6. Native polyacrylamide gel electrophoresis 

Gels for DNA nanostructure analysis were poured in TBE buffer containing 4 % (for 
large structures) to 15 % (for short oligonucleotides) acrylamide, ammonium 
persulfate and TEMED. They were run in TBE buffer at 130 V for 30 min. Staining 
was accomplished in 0.1 M NaCl solution supplemented with 2x GelRed solution. 
 
2.2.2. Polyplex formation and analysis 

2.2.2.1. Polyplex formation 

Sequence-defined oligomers 188, 278, 356, 454 and 689 were synthesized by solid-
phase-assisted synthesis as described in our previous publications [24, 30, 32]. The 
siRNA and the required amount of oligomer were separately diluted in 20 mM 
HEPES-buffered 5 % glucose pH 7.4 (HBG) in a final volume of 10 - 30 µl. Both 
solutions were pooled and incubated for 45 min at RT. 
 
2.2.2.2. Dynamic light scattering 

Polyplexes were formed with oligomer 689 in a total volume of 60 µl as described in 
the method section for polyplex formation. After incubation, the solution was 
measured in a folded capillary cell (DTS1070) using a Zetasizer Nano ZS with 
backscatter detection (Malvern Instruments, Worcestershire, UK). The refractive 
index of the solvent was set to 1.330 and the viscosity to 0.8872. The refractive index 
of polystyrene latex (1.590) was used for polyplex analysis of the particles. Each 
sample was measured three times with 10 to 17 subruns. 
 
 



2.2.2.3. siRNA binding assay 

siRNA (500 ng) or siRNA/DNA conjugate and the amount of oligomer corresponding 
to the required N/P ratio were diluted separately in HBG in a volume of 10 µL. The 
solutions were pooled and incubated at RT for 45 min. After addition of 4 µL loading 
buffer (prepared from 6 mL of glycerol, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g 
of bromophenol blue) the polyplexes were run on a 1.5 % agarose gel supplemented 
with GelRed at 90 V for 45 min. 
 
2.2.3. Cell culture 

2.2.3.1. Cultivation of cells 

Murine neuroblastoma (N2A/eGFPluc) or human cervix carcinoma (KB/eGFPluc) 
cells are each stably transfected with an enhanced green fluorescent protein GL3 
firefly luciferase fusion protein [24, 25, 36]. HeLa cells were used as wild-type cells. 
They were cultured at 37 °C in Dulbecco’s modified Eagle’s Medium with 1 g/L 
glucose (for N2A), or folate free RPMI 1640 medium (for KB, HeLa), in both cases 
supplemented with 10 % fetal bovine serum (FBS), 4 mM glutamine, 100 U/mL 
penicillin and 100 µg/mL streptomycin. For maintenance the cells were detached with 
a trypsin-EDTA solution (0.25 %) and seeded at the desired concentration. 
 
2.2.4. Transfection of N2A/eGFPluc and KB/eGFPluc cells for 
downregulation of eGFPluc 

N2A/eGFPluc and KB/eGFPluc cells were seeded in 96-well plates in 100 µL 
medium (N2A/eGFPluc: 5000 cells per well in DMEM, 10 % FBS, KB/eGFPluc: 4000 
cells per well in folate-free RPMI, 10 % FBS). After 24 h, the medium was exchanged 
with 80 µL fresh medium. The formed polyplexes containing the eGFP siRNA for 
downregulation of the eGFPluc fusion protein were added in a volume of 20 µL to 
each well. After the respective incubation time, the medium was exchanged with 100 
µL fresh medium. 48 h past the transfection the cells were incubated with 100 µL 
lysis buffer (25 mM Tris, pH 7.8, 2 mM EDTA, 2 mM DTT, 10% glycerol, 1% Triton X-
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100). 35 µL of the lysate was used for luciferase activity determination with a 
luciferase assay kit (100 mL Luciferase Assay Buffer, Promega, Mannheim, 
Germany) in a luminometer (Centro LB 960 plate reader luminometer, Berthold 
Technologies, Bad Wildbad, Germany). 
 
2.2.4.1. MTT assay 

The cells were transfected in 96-well plates as described above. 48 h post 
transfection 10 µL MTT solution was added to a final concentration of 0.5 mg/mL. 
The plate was incubated at 37 °C for 2 h for formation of the insoluble purple 
formazan. The medium was removed and the plate was stored at -80 °C for at least 1 
h. 100 µL DMSO was added to each well which dissolved the formazan and was 
quantified through its absorbance at 530 nm using a microplate reader 
(TecanSpectrafluor Plus, Tecan, Männedorf, Switzerland). Results are presented 
relative to a buffer treated control. 
 
2.2.4.2. Transfection of HeLa cells in chamber slides 
 
HeLa wild-type cells were seeded in 8-well Nunc Lab-Tek chamber slides (Thermo 
Scientific, Germany) in 300 µL medium (25,000 cells per well). After 24 h, the 
medium was exchanged with 250 µL fresh medium. The formed polyplexes 
containing the oligonucleotide were added in a volume of 50 µL to each well. After 15 
min incubation time at 37 °C, the medium was exchanged with 300 µL fresh medium. 
Fixation was accomplished by washing the wells twice with PBS (resuspending) at 
the desired time point, followed by 10 min incubation with 4% paraformaldehyde/PBS 
at RT. The wells were washed three times with PBS and stored at 4 °C up to 3 days. 
 
2.2.5. RNA stability and localization measurements 

2.2.5.1. HeLa whole cell extracts 

HeLa cells were seeded in 150 cm2 plates. After 48 h, the cells were detached with 
trypsin-EDTA solution and washed three times with PBS. The resulting pellet was 
resuspended in 4 packed cell volumes of buffer A (10 mM HEPES, 10 mM KCl, 1.5 
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mM MgCl2, 0.2 mM PMSF, 0.5 mM DTT, pH 7.9) and sonicated three times for 5 s at 
30 % amplitude with 30 s incubation on ice in between. Phenylmethylsulfonyl fluoride 
(PMSF) and dithiothreitol (DTT) were added to the buffer immediately before use. 
The cells were centrifuged for 20 min at 14,000 x g and the supernatant was 
collected. After aliquotation, the extract was frozen in liquid nitrogen and stored at -80 
°C. 
 
2.2.5.2. Cell extract measurements 

Correlation and FRET measurements in cell extract (diluted 1/10) were performed on 
a home-built pulsed interleaved excitation laser scanning confocal microscope 
described previously [102, 103] in TM buffer (10 mM Tris-Cl; 5 mM MgCl2, pH 7.5). 
For focusing the excitation light and collecting the fluorescence, a 60x water 
immersion objective with a numerical aperture (NA) of 1.27 was used (Plan Apo IR 
60x WI, Nikon). This resulted in a diffraction limited lateral focus size r of 210 nm for 
the green and 260 nm for the red channel, respectively. The laser power measured 
directly before the objective was set to 10 µW for the blue 475 nm laser and 3 µW for 
the yellow 565 nm laser. To prevent evaporation of the immersion liquid, an 
immersion oil with a refractive index of 1.33 was used. 
During the measurements, the fluorescence intensity of the two channels was 
recorded at a single point in the solution. The experiments were performed at 37 °C 
for 3 h each, divided into individual measurements of 1 min. A home written software 
package PAM was used for FCS, FCCS and FRET analysis. The analysis methods 
are described in greater detail in the appendix (see chapter 6.2.1 to 6.2.3). 
 
2.2.5.3. FLIM measurements on fixed cells 

FLIM measurements on fixed cells were performed on the same microscope as the 
cell extract measurements. For single cell images, a 1.27 NA 60x water immersion 
objective (Plan Apo IR 60x WI, Nikon) was used. Areas of 100 µm by 100 µm were 
recorded as 300 x 300 images, resulting in a pixel size of 333 nm. In order to image 
larger areas, a 0.45 NA 10x air objective was used (CFI Plan APO 10x 0.45 NA, 
Nikon). This resulted in 600 µm by 600 µm sized images with a pixel size of 1.17 µm 
for a resolution of 512 x 512 pixels. 
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For each region, 50-100 frames were recorded at a frame time of 5 s. The laser 
power of the 475 nm laser was set to 2-10 µW for the 60x objective and 10-90 µW for 
the 10x objectives to achieve a count rate between 50 kHz and 1 MHz. This 
guaranteed a high enough signal for the FLIM analysis while preventing artifacts from 
detector dead-time and photon pileup. The home written software package PAM was 
used for the phasor analysis of the FLIM data. A detailed description of the analysis 
method is given in the appendix (see chapter 6.2.4). 
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3. Results and Discussion 

3.1. DNA adaptors for siRNA polyplex formation 
 
This chapter has been partly adapted from: 
 
Philipp Heissig, Philipp M. Klein, Philipp Hadwiger, Ernst Wagner, DNA as tunable 
adaptor for siRNA polyplex stabilization and functionalization, Molecular Therapy 
Nucleic Acids (2016), 5, e288 
 
3.1.1. Design of the basic DNA nanostructure and the delivery 
agent 

The basic structure used for this approach is composed of two siRNAs directed 
against eGFP linked by a 79 nucleotides DNA backbone strand. In detail, the siRNA 
consists of a guide strand and a complementary passenger strand with either a 5’ or 
a 3’ 18 nucleotides DNA extension. Both, the siRNA guide and passenger strand 
contain two 3’ desoxythymidines linked by a phosphorothioate bond. In addition, all 
pyrimidines of the passenger strand and pyrimidines 5’ of adenines of the guide 
strand are 2’-O-Methyl modified, ensuring protection against nucleases. Via the DNA 
extensions, the siRNAs are hybridized to both ends of the DNA backbone strand 
resulting in structure 1bb2si (= 1 backbone strand + 2 siRNAs) (Figure 4a). The 
construct is formed by mixing the components in their respective molar amounts, 
heating to 95 °C and slow cooling to room temperature. The verification of the 
assembly is accomplished by building the structure from its subunits and monitoring 
the retention of each by native polyacrylamide gel electrophoresis (PAGE). All 
assemblies were clean and showed the expected difference in migration (Figure 4b).  
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Figure 4. Assembly of DNA nanostructures for polyplex formation. (a) Basic building block 
consisting of two siRNAs with a DNA extension at the 3’ or 5’ terminus of the passenger strand used 
for hybridization to both ends of a DNA backbone strand (1bb2si). Unconjugated control consisting of 
two equivalents siRNA mixed with one equivalent backbone strand (1bb2si-unconj). (b) Assembly of 
1bb2si from its subunits verified on a native polyacrylamide gel (Bb: DNA backbone strand; p5’: 
passenger strand with 5’ DNA extension; p3’: passenger strand with 3’ DNA extension; g: guide 
strand, gel cropped). Adapted from [104]. 
 
For transfection, the nanostructure was complexed with the three-armed cationic 
oligomer 689 [105]. Each arm contains three protonable succinoyl-tetraethylene 
pentamine units (Stp) for complexation of the negatively charged nucleic acids, four 
histidines which promote endosomal escape through the proton sponge effect [22] 
and terminal cysteines for polyplex stabilization through disulfide bond formation 
(Figure 5).  
 

Figure 5. Oligomer 689 for complexation of the DNA nanostructures C: cysteine; H: histidine; Stp: 
succinoyl-tetraethylene pentamine; K: lysine, structure from N to C. Adapted from [104]. 
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3.1.2. Variables in transfection efficiency 

The next step was to test whether 1bb2si has already advantages over a canonical 
siRNA format in transfection-mediated gene silencing experiments. It was mixed with 
oligomer 689 at an amine to phosphate ratio of 6 (N/P 6, including all phosphates 
from siRNA and DNA) and transfected into murine neuroblastoma N2A/eGFPluc cells 
in medium supplemented with 10 % fetal bovine serum. As these cells stably express 
an eGFP-luciferase fusion protein, luciferase is downregulated upon gene silencing 
of the eGFPluc fusion mRNA and represents a convenient quantitative read-out for 
subsequent transfections. 
The siRNA was used at a concentration of 0.36 µM and the polyplexes were 
incubated on the cells for 48 h. Luciferase knockdown is specified relative to a buffer 
treated control (Figure 6a). As expected, the canonical siRNA already exhibited a 
high gene silencing efficiency, but it was outperformed by 1bb2si. A control was 
included to verify that hybridization of the siRNA to the DNA backbone strand is 
necessary. siRNA without DNA extensions was mixed with the respective amount of 
the DNA backbone strand (1bb2si-unconj). Silencing by 1bb2si-unconj was 
comparable to that of the canonical siRNA. Thus the beneficial effect of the 
nanostructure cannot be achieved by mixing siRNA with DNA without prior 
conjugation of complementary DNA extensions. To challenge the effectiveness of 
1bb2si, the incubation time was decreased to 1.5 h and the siRNA concentration was 
reduced to 0.2 µM. While gene silencing of 1bb2si remained as good as in the 
previous experiment, the efficiency of the canonical siRNA as well as of 1bb2si-
unconj was significantly reduced. 
The previous transfections were conducted at a constant N/P ratio of 6. As extension 
of siRNA with DNA comes along with an increase in phosphates per unit, the amount 
of oligomer used for complexation of 1bb2si was higher than for siRNA. To exclude 
that the positive effect is due to the increase in oligomer amount, the transfections 
were repeated at constant oligomer concentrations of 1.7 µM and 4.1 µM 
(corresponding to a N/P ratio of 6 for both, the canonical siRNA and 1bb2si) (Figure 
6b). In both cases the prior results could be reproduced. Considering this fact, 
subsequent transfections were conducted at a constant oligomer concentration of 1.7 
µM.  
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Figure 6. Transfection efficiency of polyplexes formed with oligomer 689 and siRNA, 1bb2si or 
1bb2si-unconj. (a) Luciferase knockdown in N2A/eGFPluc cells with 0.36 µM eGFP siRNA at N/P 6 
and 48 h incubation time. (b) Comparison of luciferase knockdown at constant N/P ratio and constant 
oligomer concentration of 1.7 µM and 4.1 µM with 0.2 µM siRNA and 1.5 h incubation time. Adapted 
from [104].  
 
Furthermore the influence of the siRNA concentration with fixed oligomer 
concentration of 1.7 µM was investigated. The amount of 1bb2si and canonical 
siRNA was varied and transfection efficiency was compared (Figure 7).  
 

Figure 7. Correlation of gene silencing with siRNA concentration. Knockdown efficiency of siRNA 
CTRL, canonical siRNA and 1bb2si were compared at different concentrations, while the 
concentration of oligomer 689 was kept constant at 1.7 µM. Adapted from [104]. 
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The maximal reduction of luciferase expression was achieved for both samples at 0.1 
µM (siRNA 50 %, 1bb2si: 10 %). A further increase in concentration had no effect. 
This proves that the gene silencing efficiency of 1bb2si cannot be achieved by raising 
the siRNA concentration. Within the examined range, the advantage of 1bb2si over 
canonical siRNA is independent of N/P ratio, oligomer and siRNA concentration. 
 
To examine if the enhanced transfection efficiency is due to the formation of more 
stable polyplexes, a comparative binding assay of canonical siRNA and 1bb2si at 
different N/P ratios was performed on an agarose gel. After complexation, charge 
neutralized particles remain in the pocket while free nucleic acids migrate into the gel 
(Figure 8). For 1bb2si the retention was nearly complete already at N/P 3 indicating 
that only a low oligomer excess is necessary to form stable polyplexes proofing 
complete binding of the construct. In contrast, with canonical siRNA even at a N/P 
ratio of 24, still free siRNA could be detected. 
 

Figure 8. Binding assay for canonical siRNA and 1bb2si at different N/P ratios. Complexed 
nucleic acids remain in the loading pocket while free nucleic acids migrate into the gel (gel cropped). 
Adapted from [104]. 
 
 
3.1.3. More complex structures 

More sophisticated multimeric siRNA structures can easily be formed with the 
building block 1bb2si. By annealing three of these constructs through their DNA 
backbone, a 3-armed structure containing 6 siRNA units was assembled (3bb6si). A 
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5-armed structure containing 10 siRNA units was constructed by the same strategy 
(5bb10si) and a 4-armed with only one siRNA per arm was assembled by linking two 
1bb2si building blocks by two DNA backbone strands (4bb4si) (Figure 9). 
The larger constructs were less defined on a native PAGE gel. Various strategies 
were tested to increase the purity of the resulting nanostructures. Cooling time, 
assembly concentration and buffer composition was varied. Building blocks were pre-
annealed and assembled at a lower temperature, single-stranded domains were 
introduced at critical positions and the largest of the resulting bands was purified from 
a PAGE gel. Nevertheless, none of these approaches resulted in an increased purity. 
 

Figure 9. Assembly of star-shaped multi-siRNAs. Correctness of assembly assessed with native 
PAGE (Bb: backbone; p5’: passenger strand with 5’ DNA extension; p3’: passenger strand with 3’ 
DNA extension; g: guide strand, gels cropped). Adapted from [104]. 
 
Transfection efficiency decreased with increased number of siRNA units per 
structure. 4bb4si, unless a little less effective than 1bb2si, still exhibited a relatively 
high luciferase knockdown. In contrast 5bb10si had only minor advantages compared 
to canonical siRNA, indicating that there is no need to follow up the strategy of 
merging more than two siRNA units into one construct (Figure 10). 
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Figure 10. Gene silencing of the star-shaped multi-siRNAs. The structures were compared to the 
respective unconjugated controls (DNA backbone mixed with the corresponding equivalents siRNA). 
Adapted from [104]. 
 
 
3.1.4. Simpler structures 

Hence, the next step was to consider more simple structures than 1bb2si, which can 
be achieved by testing the subunits of 1bb2si for gene silencing (Figure 11a). This 
provides also an insight into the possible cause of the enhanced transfection 
efficiency of 1bb2si. Constructs extended by 18 DNA nucleotides either at the 3’- or 
5’-end of the passenger strand (siRNA/3’ov, siRNA/5’ov) are already slightly more 
efficacious compared to canonical siRNA. However, hybridizing either of the two 
constructs separately to the DNA backbone strand (1bb1si/3’ov and 1bb1si/5’ov, 
respectively) boosts transfection efficiency even more. Single siRNA construct 
1bb1si/3’ov performs equally well as dimer siRNA construct 1bb2si (Figure 11b).  
This indicates that attaching more siRNAs to one structure is not necessarily 
beneficial. It can even be detrimental as shown in the previous experiment. What 
seems to matter is an extension of a single siRNA by adaptor DNA. Regarding the 
attachment site of the DNA extension, the 3’ extended structures exhibited an 
increased gene silencing efficiency compared to their 5’ counterparts. 
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Figure 11. Transfection efficiency of the subunits of 1bb2si. (a) Schematic representation of the 
subunits of 1bb2si and (b) luciferase knockdown after complexation with oligomer 689. Canonical 
siRNA and 1bb2si were compared to the 5’ or 3’ passenger strand extended constructs with and 
without hybridization to the DNA backbone strand. The unconjugated controls consist of siRNA lacking 
the DNA extensions and DNA backbone strand mixed in equimolar amounts. Adapted from [104]. 
 
 
3.1.5. Single-stranded versus double-stranded 

All substructures of 1bb2si possess single-stranded DNA regions of different length 
(siRNA/3’ov: 18 bases, 1bb2si: 43 bases, 1bb1si/3’ov: 61 bases). As single-strands 
are more flexible than double-strands, this might be a requirement for stable particle 
formation and hence increased transfection efficiency. To test this hypothesis, the 
respective double-stranded equivalents were assembled and examined for luciferase 
knockdown with oligomer 689 (siRNA/3’ov-ds, 1bb1si/3’ov-ds, 1bb2si-ds) (Figure 
12a). siRNA/3’ov-ds and 1bb2si-ds resulted in a similar silencing efficiency as their 
single-stranded counterparts, indicating that a single-stranded domain is not a 
requirement. In contrast, 1bb1si/3’ov-ds showed a reduced knockdown (Figure 12b). 
The stiffness of its long unnicked double-strand might disturb particle formation. 
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Figure 12. Influence of single-stranded (ss) and double-stranded (ds) domains on transfection 
efficiency. The double-stranded equivalents corresponding to siRNA/3’ov, 1bb1si/3’ov and 1bb2si 
were assembled, transfected and compared to their single-stranded counterparts. Adapted from [104]. 
 
 
3.1.6. Optimal length of DNA sequence per siRNA 

Given the results above, the question was asked whether there is an optimum DNA 
sequence length connected to a single siRNA. Due to a better transfection efficiency 
of DNA extension at the passenger strand’s 3’-terminus compared to the 5’-
counterparts, it was decided to probe a potential DNA sequence length bias with a 
sequential DNA extension approach 3’ of the passenger strand. DNA strands with a 
complementary part to the previous extension and a 20 nucleotides part for further 
extension were used to assemble the different sized defined structures (Ext I, Ext II, 
Ext III, Ext IV, Ext V) (Figure 13a). One single-stranded nucleotide was introduced 
between the extensions to facilitate assembly. The purity of the structures was 
verified by native PAGE (Figure 13b). A positive correlation of gene silencing 
efficiency and construct size was observed. siRNA/3’ov with a single-stranded DNA 
overhang displays improved silencing activity compared with canonical siRNA without 
overhang. Double-stranded DNA extensions up to Ext II resulted in a strong increase 
in potency. Larger constructs (Ext III to V) did not increase transfection efficiency 
further (Figure 13c).  
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Figure 13. Optimal sequence length of DNA backbone. (a) Schematic representation of the 
stepwise DNA extended siRNA. Each extension step is accomplished by a DNA strand with one 
segment complementary to the previous extension and a 20 nucleotide segment for further extension. 
(b) Assembly (verified by native PAGE, gel cropped) and (c) transfection efficiency of the 
nanostructures. Adapted from [104]. 
 
This indicates that in this setup, hybridization of a single siRNA to an at least 99-
nucleotide DNA extension provides the maximum silencing effect. As all constructs 
contain a similarly long stretch of 20-nucleotide single-stranded DNA, the positive 
effect of flexible single-strandedness on polycation complexation can be ruled out as 
major cause for the enhancement. 
 
3.1.7. Reducible vs. non-reducible siRNA attachment 

In all previous experiments, irrespective of the siRNA’s terminus the DNA extension 
is covalently connected to the passenger strand via a phosphodiester linkage. It is 
possible that this chemistry prevents the siRNA from gaining full activity. This 
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assumption is supported by the difference in efficiency of the 5’ and 3’ extended 
passenger strand. To test this hypothesis a biocleavable disulfide linker was 
engineered between the RNA and the DNA extension sequence. The cytosol’s 
reducing environment should be utilized to cleave the disulfide bond, which leaves 
the siRNA in a more accessible form for the RNA-induced silencing complex.  
In order to implement this strategy two thiol modified 18 nucleotides DNA strands 
were used, each complementary to one end of the 79 nucleotides backbone strand 
that was used for the assembly of 1bb2si. An eGFP siRNA with a 5’ thiolated 
passenger strand was activated with 5,5'-dithiobis-(2-nitrobenzoic acid), coupled to 
the thiolated DNA strand and purified with high-performance liquid chromatography 
(Figure 14a).  
 
Figure 14. Purification and verification of the siRNA passenger strand–SS–DNA adaptor 
sequences. (a) Final purification was accomplished by HPLC. (b) The resulting peaks were analyzed 
with native PAGE. (5’SS: 5’ thiolated DNA adaptor, 3’SS: 3’ thiolated DNA adaptor, gel cropped) 
 
The respective constructs from the previous experiments were assembled using the 
disulfide extended siRNA (SS-1bb1si/5’ov, SS-1bb1si/3’ov, SS-1bb2si) (Figure 15a). 
The verification of the disulfide conjugates and the assemblies was again performed 
with native PAGE (Figure 14b and Figure 15b).  
All three structures showed a very efficient gene silencing activity similar to the one of 
1bb2si (Figure 15c). In contrast to the previous experiments, all DNA extensions are 
attached to the 5’ end of the siRNA passenger strand. The decreased silencing 
potential observed for the non-reducible 5’ end extended construct could be 
overcome by incorporation of the disulfide linker. The passenger strand extended 
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constructs without backbone strand (SS-siRNA/3’ov, SS-siRNA/5’ov) outperformed 
their non-reducible equivalents.  
 

Figure 15. Bioreducible conjugation of the siRNA to the DNA backbone using disulfide 
chemistry. (a) Schematic representation of the structures from previous experiments with a disulfide 
linker introduced between the 5’ passenger strand and the DNA extension. For SS-1bb1si/3’ov-INF, 
influenza peptide 7 is conjugated to the 5’ DNA extension via its cysteine (see chapter 2.3.12). (b) 
Verification of correct assembly by native PAGE (gel cropped). (c) Transfection efficiency of the 
disulfide containing constructs. Adapted from [104]. 
 
The results for the substructures of 1bb2si, the star-shaped structures, the step-by-
step extension and the bioreducible constructs could also be reproduced when 
performed at a constant N/P ratio of 6 (Appendix Figure 1). 
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3.1.8. Challenging the constructs 

As the silencing for the outstanding structures had reached a level that made it hard 
to draw conclusions on the effect of the bioreducible attachment of the siRNA or the 
larger stepwise-extended structures, the best performing constructs were further 
compared by determining their EC50 values (Figure 16). The polyplexes were formed 
at a siRNA concentration of 1 µM (corresponding to the previous transfections) and 
diluted stepwise in HBG. The siRNA concentration was plotted against luciferase 
expression, the x-axis was log10 transformed and the linear range was determined. 
The EC-50 values were calculated via EC50 = 10 ^ ((0.5 – b) / a). 
 

Figure 16. Dose-response curves for EC50 value determination. Polyplexes were formed at a 
siRNA concentration of 1 µM and diluted in HBG before they were added to the cells (Incubation time 
on the cells: 1.5 h). Adapted from [104]. 
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The difference between the structures remained non-significant with the following 
exceptions. The EC50 value of SS-1bb1si/3’ov (19.9 nM) was circa two fold higher 
than the EC50 value of the remaining structures containing the 79 nucleotides 
backbone strand. In case of the step-by-step extended siRNA, Ext IV (181 
nucleotides, EC50 of 4.4 nM) performed significantly better than Ext II (99 
nucleotides, EC50 of 11.7 nM) for which luciferase knock-down was already 
saturated at 0.2 µM siRNA (Figure 17).  
 

Figure 17. EC50 values for best performing constructs with oligomer 689. For evaluation, the X-
axis was log10 transformed and the EC50 value was determined from linear regression via                          
EC50 = 10 ^ ((0.5 - b) / a). Adapted from [104]. 
 
 
3.1.9. Luciferase knockdown is mediated by eGFP siRNA 

To demonstrate that the reduced luciferase expression upon application of the DNA-
extended constructs is really due to siRNA mediated mRNA downregulation, the 
following experiments were performed. 
The metabolic activity of the cells after transfection was determined with a MTT 
assay (Figure 18). MTT is added to the cells and its reduction to purple formazan by 
cellular oxidoreductases can be regarded as a measure for metabolic activity. None 
of the structures led to a drastic decrease in formazan production as determined at a 
siRNA concentration of 0.2 µM with a MTT assay. 
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Figure 18. Metabolic activity assay with oligomer 689. Metabolic activity after transfection with 
oligomer 689 was evaluated for all constructs by a MTT assay at an oligomer concentration of 1.7 µM 
and a siRNA concentration of 0.2 µM. Adapted from [104]. 
 
To completely rule out unspecific effects, the eGFP siRNA was replaced by a control 
siRNA for the bioreducible constructs. Thiol modified CTRL siRNA was conjugated to 
the DNA extension via disulfide exchange, as for the eGFP siRNA. The bioreducible 
CTRL equivalents were assembled and directly compared to the eGFP siRNA 
nanostructures in a transfection experiment. Luciferase knockdown of the CTRL 
constructs remained insignificant (Figure 19). 
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Figure 19. Knockdown of the eGFP-luciferase fusion protein by nanostructures containing a 
control siRNA instead of eGFP siRNA. SS-1bb1si/3’ov-CTRL, SS-1bb1si/5’ov-CTRL and SS-
1bb2si-CTRL were synthesized and assembled similar to their eGFP siRNA equivalents. Adapted from 
[104]. 
 
Taken together with the results from the MTT assay, the reduced luciferase 
expression by transfection of the eGFP siRNA nanostructures can be attributed to 
RNA interference mediated knockdown. 
 
3.1.10. Stability and particle sizes 

Furthermore a stability analysis with a DNA/RNA binding assay was performed for all 
constructs (Figure 20). As all larger structures showed already complete 
complexation at an N/P ratio of 3, the ratio was further decreased down to 0.25 to 
challenge the polyplexes even more. For the most stable polyplexes, a minor amount 
remained in the pocket at N/P ratios down to 0.5. A slight decrease in stability could 
be observed for the star-like structure, siRNA/3’ov and the double-stranded 
constructs. Differences were non-significant for the step-by-step extended structures 
and the structures containing the 79 nucleotides backbone strand. 
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Figure 20. Polyplex stability for all constructs determined by a nucleic acid gel retardation 
assay. Migration into an agarose gel (1.5 %) was determined for polyplexes prepared at different N/P 
ratios (0.25 to 24) with oligomer 689. Complexed DNA/RNA remains in the pocket, while free 
DNA/RNA migrates into the gel. Adapted from [104]. 
 
Dynamic light scattering measurements revealed that polyplexes of oligomer 689 and 
the siRNA constructs present heterogeneous populations of nanoparticles with sizes 
in the submicrometer range and high polydispersity indices (Table 1). Like for many 
related cationic carriers, probably multiple thousands of siRNAs are aggregated into 
the several hundred nanometer polyplexes. Thus the lack of significant size 
differences between the different siRNA constructs is not surprising. Results were 
comparable if a constant oligomer concentration or a constant N/P ratio was applied 
for polyplex formation. 
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Table 1. Particle size measurements by dynamic light scattering (adapted from [104]) 
 
 
3.1.11. Different polycations for siRNA transfection 

So far, only oligomer 689 was used to test the effect of DNA extension of siRNA on 
transfection efficiency. It is also of interest if these findings hold true for more 
commonly used transfection agents like linear polyethylenimine (lPEI), or for lipid-
containing formulations such as lipo-oligomer 454 (Figure 21). The latter contains six 
tyrosines and two oleic acid units which provide excellent stabilization through 
hydrophobic interactions and endosomal lysis through membrane destabilization. The 
fatty acid unit is connected to two identical arms consisting of two Stp units, three 
tyrosines for stabilization and a terminal cysteine [32]. 
 

Figure 21. Alternative delivery reagents. Commonly used polyethylenimine (left) and sequence 
defined lipo-oligomer 454 (C: cysteine; T: tyrosine; Stp: succinoyl-tetraethylene pentamine; K: lysine, 
structure from N to C) 
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Hence, siRNA, 1bb2si and 1bb2si-unconj were complexed with lPEI and lipo-
oligomer 454 at two different oligomer concentrations (corresponding to N/P 6 for 
siRNA and 1bb2si respectively) and tested for gene silencing efficiency and 
metabolic activity in N2A/eGFPluc cells (Figure 22).  
Polyplexes formed with lPEI and canonical siRNA worked at neither concentration, 
while polyplexes formed with lPEI and 1bb2si mediated gene silencing to some 
extent (Figure 22a and b). 
In contrast, if the well-stabilizing lipo-oligomer 454 was used for complexation, 
canonical siRNA already exhibited an efficient knockdown (82%) which could not be 
achieved by 1bb2si (60 %). Both constructs were compared at their optimum 
oligomer concentration (3.9 µM for siRNA, 9.2 µM for 1bb2si) (Figure 22c and d). 

Figure 22. Transfection efficiency and metabolic activity after complexation with linear PEI and 
lipo-oligomer 454. Transfection efficiency (a,c) and metabolic activity (b,d) of pure siRNA was 
compared to 1bb2si after complexation with (left) 2.2 µg/ml or 5.1 µg/ml linear PEI and (right) 3.9 µM 
or 9.2 µM oligomer 454. Adapted from [104]. 
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Consequently one can assume that the findings for oligomer 689 can be translated to 
other polycationic transfection agents such as lPEI, lacking lipidic moieties. For lipid 
containing delivery agents the additional stabilizing effect of the DNA extensions 
appears not to be necessary or may even be counterproductive. 
 
3.1.12. Attachment of functional domains to siRNA 

Stabilization of siRNA polyplexes is only one requirement for successful nucleic acid 
delivery. As mentioned in the introduction, receptor targeting for improved and 
specific intracellular uptake [36, 106] and transport across the endolysosomal barrier 
[107, 108] are additional steps where functionalization can be beneficial. Disulfide 
chemistry provides the option to attach functional units through the DNA backbone 
strand to the siRNA. INF7 is a lytic peptide known to promote endosomal escape 
[109]. It was coupled to the 3’ thiol modified DNA extension sequence by the 
peptide’s N-terminal cysteine. A construct containing one 5’ passenger strand 
extended siRNA connected via the DNA backbone to INF7 was assembled as 
previously described (SS-1bb1si/3’ov-INF) (Figure 23a). As expected, after 
complexation with oligomer 689, the inclusion of INF7 had no advantage over the 
respective construct without INF7 (SS-1si1bb/3’ov) (Figure 15c). The histidines of 
oligomer 689 already promote sufficient endosomal escape. Hence, oligomer 356, 
lacking histidines, was used to verify a positive effect of INF7 as part of the 
nanostructure (Figure 23b). Oligomer 356 is a three armed oligomer of which two 
arms contain positively charged Stp and terminal cysteines for polyplex stabilization. 
The third arm contains 24 ethylene glycol units (PEG24) for shielding and enhanced 
solubility and, in addition, folic acid to promote specific cellular uptake in folate 
receptor expressing cells [24]. 
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Figure 23. INF7 siRNA conjugate via a DNA backbone strand and oligomer 356. (a) Schematic 
representation of SS-1bb1si/3’ov-INF (b) Oligomer 356 for complexation of SS-1bb1si/3’ov-INF (C: 
cysteine; Stp: succinoyl-tetraethylene pentamine; K: lysine; PEG24: polyethylene glycol consisting of 
24 ethylene glycol units; FolA: folic acid, structure from N to C). Adapted from [104]. 
 
The polyplexes were incubated on folate receptor positive KB/eGFPluc cells with an 
incubation time of 1 h and a siRNA concentration of 0.2 µM (Figure 24). 
Indeed, SS-1bb1si/3’ov-INF showed a great increase in silencing over SS-
1bb1si/3’ov and canonical siRNA without reduction in metabolic activity, which could 
also be reproduced at a constant N/P ratio of 6, 12 and 24 (Appendix Figure 2). 
 

Figure 24. Transfection efficiency and metabolic activity of the INF7 siRNA conjugate. 
Comparison of siRNA hybridized to the DNA backbone strand with (SS-1bb1si/3’ov-INF) and without 
INF7 (1bb1si/3’ov). Incubation time was 1 h on KB/eGFPluc cells. Adapted from [104]. 
 
Folate-targeting was verified by including folate in the medium or using control 
oligomer 188, which contains alanine instead of folate (Figure 25). In both cases the 
polyplex exerted no significant reduction in luciferase expression anymore. 
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Figure 25. Folate receptor targeting of SS-1bb1si/3’ov-INF with oligomer 356. Folate targeting 
was verified by testing the formulation in a ligand competition assay, using both folate-containing 
medium (‘with folate’) and folate-free medium (‘without folate’). In addition, lack of gene silencing by 
using ligand-free oligomer 188 (similar to oligomer 356, but with folic acid ligand replaced by alanine) 
was evaluated. Adapted from [104]. 
 
Taken together these results, a highly functional polyplex out of DNA extended and 
INF7 functionalized siRNA and oligomer 356 could be formed. It harbours several 
domains to cope with the barriers for successful siRNA delivery. The DNA extension 
provides a high polyplex stability (Figure 26), PEG shields the nanoparticles from its 
environment, folate leads to receptor specific uptake and endosomal escape is 
guaranteed by INF7. 
This proves that functional units can be attached to siRNA in a very simple way via a 
tunable DNA adaptor that improves polyplex stability itself. 
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Figure 26. Binding assay for canonical siRNA and 1bb1si/3’ov-INF with oligomer 356. 
Complexed nucleic acids remain in the loading pocket while free nucleic acids migrate into the gel. 
Adapted from [104]. 
 
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3.2. Localization and integrity of small single-stranded 
RNA 
 
This chapter has been partly adapted from: 
 
Philipp Heissig, Waldemar Schrimpf, Philipp Hadwiger, Ernst Wagner, Don C. Lamb, 
Monitoring integrity and localization of modified single-stranded RNA oligonucleotides 
by ultrasensitive fluorescence methods, PLOS ONE, in press. 

3.2.1. Oligonucleotide Design 

The model sequence is 23 nucleotides in length, with a thiol modification at its 5’ and 
an amine modification at its 3’ end. The sequence was originally selected as a 
putative antagomir against microRNA200c [94, 110], which is not present in the 
tested HeLa cell line in significant quantities [111]. HeLa cells were selected to rule 
out any sequence-specific interactions, as the current study focuses on the stability 
and localization of the RNAs irrespective of their effector function. Atto488 (excitation 
maximum: 501 nm; emission maximum: 523 nm, NHS-ester modified) and TMR 
(excitation maximum: 557 nm; emission maximum: 576 nm, maleimide modified) 
were selected as a FRET pair for dual labelling at the ends and attached to the 3’ 
end via an amide bond and to the 5’ end via formation of a thioether. This approach 
provided us with a very sensitive read-out as cleavage of a single nucleotide already 
leads to separation of the two dyes (Figure 27). Cleavage can be detected using FCS 
(through a reduction in the diffusion time), FCCS (via a loss in cross-correlation 
signal) and FRET (via a loss in FRET signal, which can be detected using either 
fluorescence intensity or fluorescence lifetime measurements). After the sequence is 
exposed to the cellular environment, cleavage is mediated by nucleases. RNase A 
and RNase T2 family members cleave single-stranded RNA with high specificity and 
affinity [83, 84]. 
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Figure 27. Design of the dual-labelled RNA oligonucleotide. (A) 23 nucleotides RNA 
oligonucleotide conjugated to tetramethylrhodamine (TMR) at its 5’ end via a thioether bond and at its 
3’ end to Atto488 via an amide bond. Upon exposure to the cellular environment, the oligonucleotide 
can be degraded by various RNases. 

Three different chemical backbone modifications were selected for this approach: 
natural phosphodiester bonds were replaced with phosphorothioate bonds (PS). RNA 
residues were replaced by 2’-modified analogues. 2’-Fluoro (2’-F) and 2’-O-Methyl 
(2’-O-Me) modifications were selected as these are widely used in RNAi and 
antisense applications.   
As a stable control, a sequence consisting of a completely PS-modified backbone 
and alternating 2’-O-Me and 2’-F modifications was selected, since it was shown that 
this sequence provides adequate nuclease resistance [64]. Construct 1 is almost 
identical to the stable control with the exception of a single phosphodiester bond 
between nucleotide 10 and 11 counted from the 3’ end surrounded by two non-
modified nucleotides on each side (Figure 28). This provides a relatively stable 
sequence, which might still be susceptible to nucleolytic cleavage and can be used to 
investigate the intracellular location-specific RNase activity. Construct 2 has four PS 
and four 2’-O-Me modifications at the 5’ and the 3’ end, giving a stretch of 15 
unmodified nucleotides in the middle. This should result in faster nucleolytic 
degradation, however, leaving the dyes attached to a four-nucleotide RNA strand. 
Hence, the cell treats the residual, labelled construct similar to unlabelled RNA even 
after degradation of the unmodified domain. As a second control, a completely 
unmodified RNA strand is included to confirm the effect of the modifications (Figure 
28). 
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Figure 28. Modification patterns selected to monitor localization and integrity of the 
oligonucleotide. RNA backbone modifications to increase stability towards nucleolytic degradation: 
2’-F, 2’-O-Me and phosphorothioate. 
 
 
3.2.2. Stability evaluation in cell extracts 

Initial experiments were conducted in cell extracts to get a first hint of the stabilizing 
effect of the modifications. 100 nM of RNA was incubated in HeLa whole-cell extracts 
at 37 °C. The time course of degradation was observed every 5 min with a confocal 
microscope and the concentration of cell extract was optimized to ensure an 
appropriate degradation rate for a measurement duration of 3 h (1/10 dilution). 
Evaluation was accomplished simultaneously using FCS, FCCS and FRET, providing 
us with distinct information about the behavior of the differently modified 
oligonucleotides.  
 
3.2.2.1. Fluorescence correlation spectroscopy 

The diffusion time of Atto488 or TMR containing particles through the focus was 
determined using the temporal auto-correlation analysis of the fluorescence intensity 
fluctuations (Figure 29a). Since pulsed interleaved excitation (PIE) was used [102], 
the influence of spectral crosstalk was removed resulting in correlation functions that 
are not biased by the presence of the other dye. 
The diffusion coefficient inversely correlates with the particle size. This means that 
the diffusion coefficient of the dye conjugate increases when nucleotides are 
removed from the RNA construct over time. To quantify this degradation, an 
autocorrelation function (ACF) for two diffusing components was used to fit the data. 
In this simplified assumption, the slow component represents the full construct while 
the fast component corresponds to a digested dye-RNA fragment. The decrease in 
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the amplitude of the slow component was taken as a measure for oligonucleotide 
degradation.  

Figure 29. Monitoring degradation of the dual-labelled constructs in cell extracts using FCS. (a) 
The diffusion time is extracted from the autocorrelation function. Degradation of all four constructs over 
200 min is analyzed by autocorrelation of the (b) Atto488 channel and the (c) TMR channel. The 
curves were normalized to 1 for the initial data-point. The measurements were performed by 
Waldemar Schrimpf (Department of Physical Chemistry, LMU). 
 
The degradation dynamics of the different RNAs can be nicely observed from the 
FCS signal of Atto488. While no change in ACF was observed for the stable control 
and construct 1, the instable control and construct 2 degraded with time (Figure 29b). 
Assuming a monoexponential decay, the half-life of construct 2 was 4.7 times longer 
than for the instable control (construct 2: 220 min, instable control: 47 min) (Table 2). 
This stabilizing effect is attributed to the chemically modified ends of construct 2 
(Figure 28). A single cleavage event at the unmodified position of construct 1 might 
not be recognized by this technique, as the dyes still contain a relatively long stretch 
of modified RNA which contributes to the slow component in the fit.  
Analysis of the ACF from FCS measurements of TMR provided similar results with 
construct 1 and the fully modified RNA strand being more stable than construct 2 and 
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the unprotected RNA strand (Figure 29c). However, the change in the diffusion 
coefficient for the unprotected RNA strand was not as large as expected. This could 
be due to the association of the TMR with cellular proteins, as FCS measures only 
the mobility of the probe. The FCS measurements of TMR showed a high variation in 
diffusion coefficients of the slow component between the different constructs, 
suggesting that aggregation may play a crucial role. To avoid the complications of a 
purely FCS based analysis, a fluorescence cross-correlation analysis was performed 
on the same data. 
 
Table 2. Half-lives of the differently modified constructs in HeLa cell extracts 

 
 
3.2.2.2. Fluorescence cross-correlation spectroscopy 

In FCCS, the fluorescence intensity fluctuations in one channel (corresponding to 
Atto488) are correlated to the fluctuations in the other channel (corresponding to 
TMR). Hence, when a RNA carries both labels, a cross-correlation signal will be 
observed. A single cleavage event leads to a complete loss in the cross-correlation 
amplitude, which makes this technique very sensitive (Figure 30a). By combining 
FCCS with PIE [102, 112] spectral cross-talk is removed, further increasing the 
sensitivity of the technique. This method is less biased towards cellular protein 
association compared to FCS, as the cross-correlation does not depend on the size 
of the construct. The FCCS results were consistent with FCS, with the exception that 
construct 1 revealed a slight degradation compared to the stable control, which is in 
accordance with the increased sensitivity of FCCS (half-life of 610 min). As 
determined by this technique, the half-life of construct 2 (172 min) was 1.9 times 
longer than the half-life of the instable control with 89 min (Figure 30b and Table 2). 
 
FCS (blue channel) FCCS FRET (lifetime) FRET (intensity)
stable CTRL > 1000 min > 1000 min 401 min 564 min
Construct 1 > 1000 min 610 min 148 min 331 min
Construct 2 220 min 172 min 170 min 239 min
instable CTRL 47 min 89 min 103 min 128 min



Figure 30. Monitoring degradation of the dual-labelled constructs in cell extracts using FCCS. 
(a) The integrity of the constructs is extracted from the amplitude of the cross-correlation function. (b)  
Degradation of all four constructs over 200 min is analyzed by FCCS. The curves were normalized to 
1 for the initial data-point. The measurements were performed by Waldemar Schrimpf (Department of 
Physical Chemistry, LMU). 
 
3.2.2.3. Förster resonance energy transfer 

Another measure of dual-labelled RNA integrity is FRET, which can be evaluated 
based on fluorescence intensity ratios or via the fluorescence lifetime of the donor 
dye. Non-radiative energy transfer from the donor to the acceptor dye depends on 
their spatial separation and can be observed for distances up to 10 nm. Hence, the 
intact double-labelled RNA should give a significantly higher emission in the red 
channel (TMR) and a reduced lifetime for the donor upon excitation of Atto488 than 
the cleaved construct (Figure 31a and b). Similar to FCCS, this technique is sensitive 
to a single cleavage event. Intensity based FRET is calculated from the ratio of the 
red signal after Atto488 excitation to the sum of red and green fluorescence after 
Atto488 excitation, corrected for spectral crosstalk of Atto488 into the acceptor 
channel and direct excitation of TMR. A parameter that was not accounted for was 
incomplete labelling of the RNA and possible degradation of the RNA before the 
experiment. However, since the RNA degradation in cell extracts was expected to be 
exponential, these parameters would only change the initial values and not affect the 
rate constants. FRET also provides information on the conformation of the RNAs. As 
transitions between coiled and stretched conformations change the distance between 
the dyes, the measured FRET efficiencies depend on the conformational state. 
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Furthermore, FRET measurements can be sensitive to artifacts from pH or 
aggregation dependent quenching of the dyes.  
 

Figure 31. Monitoring degradation of the dual-labelled constructs in cell extracts using FRET. 
FRET efficiency is determined from (a) the fluorescence intensities and (b) the donor fluorescence 
lifetime based FRET using a phasor analysis. Degradation of all four constructs over 200 min is 
analyzed by (c) intensity based FRET and (d) donor fluorescence lifetime based FRET. The curves 
were normalized to 1 for the initial data-point. The measurements were performed by Waldemar 
Schrimpf (Department of Physical Chemistry, LMU). 
 
The results from the FRET experiments showed that the instable control was 
degraded the fastest with half-lives of 102 min and 128 min for measurements based 
on lifetime and intensity, respectively. As expected, construct 1 was more stable than 
construct 2 for the intensity measurements (half-life construct 1: 331 min, half-life 
construct 2: 239 min). For the lifetime based analysis, the stability-difference between 
the two constructs was insignificant (half-life construct 1: 149 min, half-life construct 
2: 170 min). Interestingly, the stable control revealed a slight decrease in FRET 
efficiency over time (half-life: 401 min for lifetime based and 564 min for intensity 
based FRET) (Figure 31c and d, Table 2).  
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As no degradation is visible when evaluated by FCS or FCCS, this might be due to 
interactions with cellular components affecting the conformation of the construct or 
the lifetime of the Atto488.  
 
Taken together, the results obtained from the different read-outs show that the extent 
of modification of the construct strongly correlates with its stability in cell extracts. 
Highly sensitive data for cleavage of just a single nucleotide can be obtained by 
FCCS. FRET provides additional information on the conformational state of the RNA 
while FCS detects association with cellular components. Applying only a single 
technique might lead to misinterpretation of the data, as artifacts like quenching, 
conformational changes and aggregation might be mistaken for stability related 
issues.  
 
3.2.3. Measurements in cells 

3.2.3.1. Transfection 

After having elucidated the fate of the chemically modified oligonucleotides in cell 
extracts, the next question was if the results hold true when the RNAs are transfected 
directly into HeLa cells. The sequence defined cationic oligomer 278 [25, 30] was 
selected as a carrier, as it displays fast cellular uptake, which is indispensable for a 
time course degradation experiment. 278 is a U-shaped lipo-oligocation consisting of 
a protonable backbone of three succinoyl-tetraethylene pentamine (Stp) units for 
complexation of the nucleic acid. Terminal cysteines introduced for polyplex 
stabilization by disulfide formation are separated from the Stp units by branching 
lysines, which are connected to four linoleic acids which aid particle stabilization 
through hydrophobic interactions (Figure 32). Polyplexes were formed using oligomer 
278 and the respective modified oligonucleotide and incubated on HeLa cells at a 
RNA concentration of 167 nM. After 15 min, non-bound polyplexes were washed 
away from the cells followed by an additional incubation at 37 °C. Biological 
processes were stopped at different time points by fixation with 4 % 
paraformaldehyde and the cells were examined under a confocal microscope.  
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Figure 32. Oligomer 278 for transfection of the constructs into HeLa cells. U-shaped, sequence 
defined cationizable lipo-oligomer 278 for complexation of the dual-labelled RNAs (C: cysteine, K: 
lysine, Stp: succinoyl-tetraethylene pentamine, linA: linoleic acid, structure from N to C). 
 
 
3.2.3.2. Fluorescence intensity 

The fluorescence intensities of the four modification patterns were investigated after 
15 min, 1 h, 6 h and 24 h (Figure 33a). The polyplexes were not immediately 
released after endosomal uptake. In fact, the RNA constructs continuously enter the 
cytosol over a longer time span. This accumulation is counteracted by RNA 
degradation and subsequent depletion from the cells. The fluorescence intensities 
that were observed for the four constructs at different time points reflect this balance 
(Figure 33b). In the measurements, the increase of the fluorescence intensity 
correlated with the extent of modification and, for the two most stable constructs, also 
with the duration of the incubation time after the transfection. For the less stable 
patterns, even a slight decrease in RNA concentration was observed over time. 
Especially the instable control showed very low fluorescence intensity at all time 
points. After the construct is taken up, it is almost immediately degraded by RNases. 
Since the dyes are no longer coupled to RNA, they are not retained in the cells, 
resulting in a low steady-state concentration.  
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Figure 33. Fluorescence intensities of HeLa cells in culture after transfection with oligomer 278. 
(a) Fluorescence intensity images of the HeLa cells 15 min, 1 h, 6 h and 24 h after transfection of the 
four different modification patterns. The contrast level is equal for all images. The scale bar represents 
200 µm. (b) Average fluorescence count rate of the cells at the different conditions shown in (a). The 
error bars represent the standard deviation of three independent measurements. The measurements 
were performed by Waldemar Schrimpf (Department of Physical Chemistry, LMU). 
 

	
Taking a closer look at the cells, one can distinguish between two populations: cells 
showing a high fluorescence intensity in the nucleus and cells showing a higher 
fluorescence intensity in the cytosol (Figure 34). The cells that show a strong nuclear 
translocation of the constructs also have a brighter total intensity. This nuclear 
translocation is not present for the instable control as degradation dominates over 
other cellular processes.  
 

 
Figure 34. Nuclear translocation of the dual-labelled RNAs in HeLa cells. Cells with increased 
RNA concentrations in the nucleus show also an increased overall brightness for the different 
stabilized constructs. The upper and lower images are the same. The contrast for the upper images is 
set to allow observation of the bright cells whereas, on the bottom images, the contrast is set to better 
visualize the dim cells. The scale bar is 20 µm. The measurements were performed by Waldemar 
Schrimpf (Department of Physical Chemistry, LMU). 
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3.2.3.3. Fluorescence lifetime in cells 
 
Using fluorescence lifetime imaging microscopy (FLIM), one can gather information 
regarding the integrity of the RNA constructs at different locations within the cells. 
Images were collected from cells that had been incubated at 37 °C for 15 min, 1 h, 6 
h and 24 h after transfection using oligomer 278 as the carrier. Due to quenching via 
FRET, Atto488 in intact constructs shows a reduced fluorescence lifetime compared 
to that in cleaved RNA fragments. Thus, the lifetime can be used as a read-out for 
the progress of RNA degradation. The image is scanned pixel by pixel and the 
lifetime at each spot is determined using the phasor approach to FLIM (Figure 35 and 
Figure 37). 
The phasor approach is a fit-free way of analyzing lifetime data in the Fourier space 
by utilizing certain rules that simplify the analysis [113, 114]. The first of these rules is 
the fact that all purely mono-exponential decays lie on the universal circle centered at 
(0.5,0) with a radius of 0.5. The exact position on the circle is determined by the 
fluorescence lifetime, with short decays lying close to the (1,0) point while long 
lifetimes are closest to the origin. The second important rule is that mixtures of 
different lifetime species result in a phasor that is a linear combination of the two 
species. The vector is intensity-weighted meaning that any mixture of two lifetimes 
will lie on a straight line connecting the phasors of the pure species. Knowing the end 
positions of this line makes it possible to calculate the fractional contributions for any 
unknown mixture. 
In the phasor plot, the combined FLIM data of all measurements and patterns show a 
distribution along a line connecting the mono-exponential decays at 4.1 ns 
(corresponding to unquenched Atto488) and at 1.25 ns (corresponding to the intact 
construct showing FRET) (Figure 37).  
 
However, there are other sources of fluorescence quenching that need to be 
considered. The first one is quenching in densely packed particles (vesicles or 
polyplex aggregates). These regions are recognizable as small bright spots in the 
images and form a tail towards very short lifetimes in the phasor plot, as shown for 
the stable control construct with and without the acceptor dye (TMR) 24 h after 
transfection  (Figure 35). 
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Figure 35. Quenching in polyplexes. (a) Phasor histogram of the FLIM images shown in panel b. 
The red, green and blue dotted ellipsoids were used to color code the individual pixels in panel b. The 
magenta ellipsoid highlights the phasor of pure polyplexes (made with the stable control RNA) 
measured in vitro. (b) FLIM images of the stable control both with (left) and without (right) the acceptor 
dye (TMR) after 24 h incubation (upper panels). The contrast is set to visualize the shorter lifetime of 
the bright polyplex aggregates in the cells (lower panels). The image contrast was scaled to better 
visualize the cells. The scale bar is 20 µm. The measurements were performed by Waldemar Schrimpf 
(Department of Physical Chemistry, LMU). 
 
In the control construct without the acceptor dye, quenching in these spots is still 
noticeable, but much reduced. This suggests that increased FRET between the 
densely packed RNAs is the main quenching source, but that self-quenching by the 
dyes or quenching from the carrier oligomer may also play a role. This is also 
noticeable with intensity based FRET (Figure 36). Using an upper intensity threshold, 
these aggregates can be easily filtered out and removed from further analysis.  
A second source of lifetime changes that do not depend on the integrity of the 
constructs are conformational changes of the free RNAs as FRET is highly sensitive 
to the distance between the donor-acceptor dye pair.  
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Figure 36. Intensity based FRET images.  Donor (green) and acceptor (red) signal after donor 
excitation is shown 15 min (a) and 24 h (b) after transfection for construct 2 and 24 h after transfection 
for the stable control with (c) and without (d) acceptor dye (TMR). The scale bar is 20 µm. The 
measurements were performed by Waldemar Schrimpf (Department of Physical Chemistry, LMU). 
 
In order to investigate the degradation of the RNAs, the distribution of the pixels of 
the different patterns at different time points were plotted (Figure 37 and Figure 38a-
d) and the average value was extracted using a Gaussian fit (Figure 38e). The pixel 
positions along the line (i.e. the average pixel lifetimes) can also be depicted in the 
images using a color code (Figure 37). Blue represents a short fluorescence lifetime 
corresponding to an intact construct. Red represents a long lifetime indicating a 
degraded oligonucleotide. 
 



 
Figure 37. Phasor FLIM analysis in cultured HeLa cells.  (a) The phasor histogram of images 
shown in panel b and c. The grey dotted line indicates the axis used for color-coding the FLIM images 
in b and c. (b) FLIM images 24 h after transfection of the stable control RNA, construct 1, construct 2 
and the stable control RNA without TMR in cultured HeLa cells. The scale bar is 30 µm. (c) FLIM 
images for all measured constructs and time points. These measurements are the same as those 
shown in Figure 33. The scale bar is 200 µm. The measurements were performed by Waldemar 
Schrimpf (Department of Physical Chemistry, LMU). 
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The dual-labelled stable control and construct 1 do not show any change in lifetime 
over the whole time course of 24 h (Figure 37c rows 3 and 4). This lack of 
degradation also explains the strong accumulation of the constructs within the cells. 
However, taking into account the fact that construct accumulation is a little stronger 
for the stable control, one can assume that there is a slight degradation of construct 
1, which increases the ability of the cells to dispose of the oligonucleotide. 
Considering the fact that the cells are constantly fed with intact constructs from 
endosomes and aggregates, it is not surprising that the lifetime experiment reveals 
no significant differences (Figure 38a and b) as, at any point, the amount of degraded 
RNAs is negligible compared to that of the intact constructs. Construct 2 nicely shows 
an increase in lifetime over the time course, corresponding to degradation of the 
construct. Especially highly fluorescent cells have a long lifetime, originating from 
accumulation of the degraded oligonucleotide (Figure 37c row 2). For the instable 
control, the observed fluorescence lifetime increases slower than for the more stable 
construct 2 (Figure 38 c and d). However, considering the very low fluorescence 
intensity of the control, it is most likely that the oligonucleotides are degraded and 
depleted from the cells so fast that the lifetime values mostly originate from intact 
constructs that have just been released into the cytosol. In contrast, construct 2 
Atto488 still has a stabilized four nucleotides stretch of RNA attached, which is not as 
easily expelled from the cells as free dye. This is supported by the fact that the 
fluorescence intensity of construct 2 images is significantly higher than that of the 
instable control images. 
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Figure 38. Quantification of the fluorescence lifetime measurements. (a-d) Distribution of the 
pixels along the line connecting the mono-exponential decays at 4.1 ns and at 1.25 ns in the phasor 
plot for the four modification patterns. (e) Summary of the average fluorescence lifetimes of the cell 
populations shown in panels a-d using a Gaussian fit to the distribution. The error bars represent the 
standard deviations of three independent measurements. The measurements were performed by 
Waldemar Schrimpf (Department of Physical Chemistry, LMU). 
 
Short lifetimes that originate from FRET and represent a high construct integrity can 
be distinguished from unspecific quenching effects by testing also the control sample 
where the stable control pattern was conjugated only to Atto488. Since no FRET can 
occur, any differences in lifetime observed are due to unspecific quenching. As 
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expected, the fluorescence lifetime was long in the cytosol as well as the nucleus 
after 1 h and 24 h (Figure 39).  
 

Figure 39. Fluorescence lifetime imaging microscopy of the completely stabilized 
oligonucleotide conjugated to Atto488 only. The fluorescence lifetime was measured 1 h and 24 h 
after transfection to HeLa cells. The scale bar is 100 µm. The measurements were performed by 
Waldemar Schrimpf (Department of Physical Chemistry, LMU). 
 
The small bluish dots in the cytosol are visible for all constructs and most probably 
possess a high density of Atto488 leading to quenching through aggregation (Figure 
35 and Figure 36). Possible sources are endosomes that have not yet released the 
constructs or polyplexes that have not disassembled. Consequently, as soon as the 
oligonucleotides are liberated into the cytosol or the nucleus, a decreased lifetime 
can be assigned to FRET originating from an intact construct.  
 
In general, the measured lifetime values can be explained by a balance originating 
from the release of intact RNA, its degradation and subsequent depletion from the 
cells. Longer stretches of nucleotides accumulate in the cells and are transported into 
the nucleus when the cells are transfected with high efficiency. With decreasing 
length of the stabilized RNA stretch, depletion from the cells is favored. 
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4. Conclusions 

4.1. DNA as a tunable adaptor for siRNA polyplex 
stabilization and functionalization 

This chapter has been partly adapted from: 
 
Philipp Heissig, Philipp M. Klein, Philipp Hadwiger, Ernst Wagner, DNA as tunable 
adaptor for siRNA polyplex stabilization and functionalization, Molecular Therapy 
Nucleic Acids (2016), 5, e288 
 
This study demonstrates how siRNA can be extended by DNA adaptors to improve 
complex formation with sequence defined cationic oligomers, resulting in improved 
gene silencing efficiency. Several DNA/siRNA nanostructures ranging from DNA 
extension of one siRNA up to structures where two to ten siRNA units are merged 
into one construct were tested. Delivery could be improved remarkably after 
complexation with the three-armed cationic oligomer 689. Interestingly, the larger 
structures containing multiple siRNAs were less potent than the simple ones with one 
or two siRNA units. A possible reason for this is that a linear structure conjugated to 
only one siRNA is easier accessible by the RISC complex. The observed key 
criterion for efficacy was the simple extension of siRNA with DNA to provide a 
sufficient number of negative charges. 
However, larger structures might have advantages over the linear constructs when 
delivered without a transfection agent. Without complexation with cationic oligomers, 
the linear structures are prone to degradation by nucleases. The compact 
organization of origamis or polyhedrons makes the constructs less accessible for 
nucleases due to steric hindrance. 
A step-by-step extension of a single siRNA could show that a prolongation of up to 
181 DNA nucleotides results in a significant improvement of transfection efficiency 
with oligomer 689. In polyplexes with other transfection agents, the siRNA might have 
a different optimal DNA extension length. But as the canonical siRNA format is 
constrained to 21 to 23 base pairs, it is unlikely that this represents the optimum. 
Therefore DNA extension of siRNA might have advantages in many formulations. 
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The optimal extension length however has to be evaluated for each delivery agent 
separately. 
An additional finding was that a 3’ DNA extended siRNA passenger strand is 
advantageous over a 5’ extended one. Probably 5’ DNA extension disturbs RISC 
loading or passenger strand removal. An influence of differences in secondary 
structure formation of the 3’ and the 5’ extension being responsible for this effect is 
unlikely, as the benefit of the 3’ extended structures is also present when the 
extension is hybridized to a DNA backbone strand. So when conjugating siRNA to 
DNA, the 3’ end of the passenger strand should be chosen as attachment site. 
Figuring out the reason behind this would go beyond the scope of this work. 
The differences between 3’ and 5’ passenger strand extension indicates that steric 
hindrance is an issue to consider even for the simple structures, which carry only an 
18 nucleotides extension. To overcome this limitation a reducible disulfide linker was 
introduced between the 5’ siRNA passenger strand and the DNA extension that 
should liberate the siRNA from the DNA adaptor in the cytosol. With this strategy, it 
was possible to enhance the performance of the 5’ extension constructs to the level 
of their 3’ counterparts. Hence, if siRNA should be modified on both ends of the 
passenger strand a reducible conjugation should be considered for the 5’ terminus. 
However, including bioreducible disulfides comes along with a possible 
destabilization during therapeutical application. Even before the nanoparticle has 
entered the cell, extracellular Glutathione might promote disulfide reduction and 
exchange [115]. Furthermore, disulfides have to be handled with care during 
synthesis as they are instable in a reducing environment.  
Eventually we could lift the findings to a more general level as DNA extension of 
siRNA is also beneficial when using linear PEI as transfection agent. This is well in 
agreement with the previous finding that showed enhanced activity of linear PEI 
when using sticky siRNA [52]. 
It was assumed that the dominating reason for an improved transfection efficiency of 
the nanostructures is their better complexation with polycations. Consequently the 
question was asked if this finding can be reproduced for oligomers which form 
already stable particles with canonical siRNA. Lipo-oligomer 454 containing fatty 
acids and tyrosines for polyplex stabilization was used as a model [32]. Transfection 
efficiency could not be further improved by DNA extension of siRNA. The already 
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known high siRNA polyplex stability apparently makes an additional stabilizing effect 
by DNA extension dispensable.  
Importantly, it was also shown that a DNA backbone strand cannot only be used for 
extension or connection of multiple siRNAs, but also to include other functional 
domains in a very simple way. Thiolated DNA extensions can be conjugated to any 
thiol containing functional molecule. Through hybridization with the DNA backbone 
strand the functional unit can be linked to siRNA. As a proof of concept, the 
endosomolytic peptide INF7 was conjugated via a 79 nucleotides DNA adaptor to a 
siRNA. The INF7-modified DNA backbone strand, which can be further optimized in 
terms of length and structure for each application, improved transfection efficiency 
and polyplex stability with the multifunctional oligomer 356. 
This strategy resulted in a straightforward construction of defined folate-receptor 
targeted siRNA polyplexes containing all key elements for functional delivery, 
including particle surface shielding by polyethylene glycol, bioreversible stabilization 
by disulfide bonding, folate as receptor-targeting ligand, and INF7 for endosomal 
escape. The advantage of this strategy is the simplicity of how complex structures 
can be assembled out of building blocks. Synthesis is facilitated as the building 
blocks are constructed independently from each other (in this case the siRNA and the 
INF7 peptide). Various combinations of the functionalized DNA strands can be 
achieved simply by designing the sequences of the backbone. Assembly requires 
nothing but mixing the building blocks and the backbone, heating and slowly cooling 
the solution to room temperature, which makes a final purification dispensable.   
 
Even though this work is providing an overview over extending siRNA for better 
polyplex stabilization, plenty of possibilities still remain to be examined. 
This includes for example the effect of replacing the DNA adaptors with RNA. RNA is 
structurally more flexible than DNA, which could have an impact on complexation 
with polycations. Furthermore, RNA is degraded faster than DNA which might 
improve intracellular siRNA availability, but decrease extracellular nanostructure 
stability. It would also be interesting to investigate if secondary structure of the single-
stranded extensions influences polyplex formation. The difference between stretches 
containing a single base unable to hybridize could be compared with strands that 
form extensive secondary structures. 
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In summary, the current work emphasizes that designing polyplexes for siRNA 
delivery can not only be accomplished by optimization of the cationic carrier, but also 
by modification of the siRNA itself. DNA is a highly suitable backbone for improving 
stability of the polyplexes and for functionalization of the siRNA. 
 
 
4.2. Localization and integrity of small single-stranded 
RNA 
 
This chapter has been partly adapted from: 
 
Philipp Heissig, Waldemar Schrimpf, Philipp Hadwiger, Ernst Wagner, Don Lamb, 
Monitoring integrity and localization of modified single-stranded RNA oligonucleotides 
by ultrasensitive fluorescence methods, PLOS ONE, in press. 

The stability of short single-stranded RNA oligonucleotides modified with 
phosphorothioates, 2’-O-Me and 2’-F was compared in cellular extracts and in 
cultured cells. By evaluating the degradation with FCS, FCCS and FRET (both 
intensity and fluorescence lifetime based) in cell extracts, it was concluded that each 
methodology provides distinct information on the behavior of the two-dye labelled 
constructs, which is indispensable to understand the fate of those RNAs. With FCCS, 
the integrity of the connection between the two dyes is monitored with very high 
sensitivity. Additional information on interactions with cellular components is detected 
by FCS, but at the expense of sensitivity for RNA degradation. FRET is not only 
sensitive towards construct cleavage, but can also detect conformational changes as 
FRET efficiency depends on the distance between the two dyes. All techniques were 
necessary to minimize biases in the analysis from unspecific effects like aggregation, 
interactions with cellular components, quenching or conformational changes. Taking 
the results from the four techniques together, the non-modified oligonucleotide was 
on average degraded 2.2 times faster than the construct with the modified ends 
(construct 2) and 8.3 times faster than the almost completely modified construct 1. A 
completely stabilized stable control was not degraded in cell extracts. These findings 
are in good agreement with previous works on chemically modified RNAs [116]. 
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Fluorescence lifetime measurements in cells in culture revealed interesting 
information on modification dependent integrity and localization of the 
oligonucleotides. It was concluded that non-stabilized single-stranded RNA 
oligonucleotides are degraded before a significant accumulation of the constructs can 
occur. For the stabilized constructs, on the other hand, intracellular fluorescence 
intensity increased with the extent of modification. Construct 2, with only a few 
modifications, showed no continuous increase in fluorescence intensity, but the 
equilibrium concentration was significantly higher than for the instable control. For 
construct 1 and the stable control, however, the release of the constructs into the 
cytosol far exceeded their degradation and depletion, leading to an accumulation 
over time. The short, non-modified region in construct 1 slightly decelerated the 
accumulation within the cells. Furthermore, in cells displaying a high fluorescence 
intensity, the oligonucleotides were transported into the nucleus. A high transfection 
rate is a prerequisite for the domination of the nuclear translocation mechanism over 
the depletion mechanism. 
The lifetime of the constructs in living cells can be explained by a balance between 
release of the intact constructs from endosomes and polyplexes, degradation by 
RNases and subsequent depletion of the fluorophores from the cells. The difference 
of construct 1 and the stable control observed for the fluorescence intensities has no 
significant effect on the lifetime measurements, since the small contribution of the 
cleaved constructs is drowned out by the majority of intact RNAs. Construct 2 
transfected cells reached a plateau in lifetime after 6 h with a mean fluorescence 
lifetime that is ca. 0.35 ns longer than for the stable control. The slower increase in 
the fluorescence lifetime over time for the instable control can be attributed to the fast 
complete degradation and depletion of the dyes from the cells directly after their 
release into the cytosol. The lifetime values mostly originated from the few intact 
constructs immediately after their liberation. 
Taken together considering also the results from the cell extract measurements, it 
was concluded that a fully PS modified backbone and alternating 2’-O-Methyl and 2’-
Fluoro modifications provide complete resistance towards nuclease activity for single-
stranded oligonucleotides under the experimental conditions. A single unmodified 
region accelerates degradation and slightly reduces accumulation, but still shows 
highly increased RNase resistance when compared to non-modified RNA. Stability 
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decreases with the length of the stretch of unmodified nucleotides as demonstrated 
by the difference between construct 1 and construct 2.  
With FLIM, information on the endosomal release, liberation from polyplexes and 
localization dependent stability of any double-labelled construct after its transfection 
was obtained. Hence, this technique can be a useful tool to understand more about 
the behavior of transfected oligonucleotides and their dependency on different 
chemical modification patterns. The information on localization-dependent integrity 
and availability can be used to figure out the bottlenecks of oligonucleotide delivery 
and help to specifically improve the functionality of a carrier. 
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5. Summary 

Over the last decades, various potential RNA therapeutics have been developed. 
Even though their mechanism of action is mostly directed by complementary base 
pairing, the applications are versatile. What makes the approach so powerful is that 
one can interfere with almost any cellular process by simply selecting the appropriate 
sequence. The most prominent examples are double-stranded siRNAs or microRNAs 
which downregulate mRNA through the RNA interference mechanism. However, also 
single-stranded nucleic acids can act as antisense oligonucleotides and disturb 
almost any stage of mRNA processing coding for the protein of interest.  
The difficulty that comes along with nucleic acid therapeutics is the functional delivery 
to the intracellular site of action. A promising approach is the complexation of the 
negatively charged nucleic acids with cationic oligomers, which not only neutralize 
the charge of the complex, but can be used to incorporate shielding, targeting and 
endosomolytic domains. The carrier can be optimized with respect to stability and 
functionality according to its application. However also the oligonucleotide offers a 
level for fine-tuning the nanoparticle, as it can easily be extended, chemically 
modified or functionalized by itself. 
The first part examined how DNA can be used to extend and functionalize siRNA for 
improved polyplex stability and transfection efficiency with the three-armed cationic 
oligomer 689. Already an 18 nucleotides DNA extension increased polyplex stability 
and silencing potential significantly. Joining several siRNAs into one construct did not 
increase reporter protein downregulation compared to the single siRNA containing 
equivalents. Gradually extending siRNA with double-stranded DNA enhanced the 
transfection efficiency until a plateau at 181 nucleotides. The beneficial effect of the 
extensions was reproduced with linear polyethylenimine as transfection agent. In 
contrast, with lipo-oligomer 454 the DNA extensions had no positive effect, as the 
fatty acid-induced stabilization of the polyplexes is already sufficient with canonical 
siRNA. Lastly, siRNA was successfully functionalized with the endosomolytic peptide 
INF7 via a DNA adaptor. This proved that the direct modification of siRNA with DNA 
is a very useful tool for polyplex stabilization and functionalization, as it can be easily 
optimized by varying the length, structure and conjugated functional units. 
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The second part focused on the stability and localization of small RNAs after 
exposure to cellular environment. More precisely, the behavior of four single-stranded 
dual-fluorophore labelled RNA oligonucleotides, which were chemically stabilized to a 
different extent, was tested. Firstly, the degradation of those constructs was 
monitored in HeLa cell extracts with different ultrasensitive fluorescence methods like 
fluorescence correlation spectroscopy, fluorescence cross-correlation spectroscopy 
and Förster resonance energy transfer. The extent of chemical modification 
correlated with the degradation rate. Considering only one technique leads to 
misinterpretation of the results due to unspecific effects like quenching, aggregation 
or conformational changes. Secondly, the localization dependent integrity of the four 
oligonucleotides was examined in HeLa cells with fluorescence lifetime imaging 
microscopy after transfection with a cationic transfection agent. The extent of 
chemically stabilizing RNA modification correlated with integrity and an increased 
cellular accumulation. Especially the cells that were transfected with high efficiency 
transported the oligonucleotides into the nucleus. Overall, the observed lifetime 
values can be explained by a balance between uptake of the constructs from 
endosomes, degradation by cellular nucleases and depletion from the cells, which is 
favored when the RNA is removed from the dyes.  

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6. Appendix 

6.1. Abbreviations 

2'-F   2’-Fluoro 
2’-O-Me  2’-O-Methyl 
ACF   Autocorrelation function 
Ago   Argonaute 
bb   Backbone 
bp   Base pair 
CTRL   Control 
DMEM  Dulbecco's modified eagle medium 
DMSO  Dimethylsulfoxide 
DNA   Desoxyribonucleic acid 
ds   Double-stranded 
DTNB   5,5'-Dithiobis-(2-nitrobenzoic acid 
DTT   Dithiothreitol 
EC50   Half maximal effective concentration 
EDTA   Ethylenediamine tetraacetic acid 
eGFP   Enhanced green fluorescent protein 
EtOH   Ethanol 
FBS   Fetal bovine serum 
FCS   Fluorescence correlation spectroscopy 
FCCS   Fluorescence cross-correlation spectroscopy 
FDA   Food and drug administration 
FLIM   Fluorescence lifetime imaging microscopy 
FolA   Folic acid 
FRET   Förster resonance energy transfer 
HBG   HEPES buffered glucose 
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC   High performance liquid chromatography 
INF7   Endosomolytic peptide #7 derived from influenza HA2 
IRF   Instrument response function 
KCl   Potassium chloride 
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LinA   Linoleic acid 
lPEI   Linear polyethylenimine 
miRNA  microRNA 
mRNA  Messenger RNA 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N/P ratio  Amine/phosphate ratio 
NA   Numerical aperture 
NaCl   Sodium chloride 
NHS   N-hydroxysuccinimid 
nt   Nucleotides 
ov   Overhang 
PAGE   Polyacrylamide gel electrophoresis 
pcv   Packed cell volume 
PEG   Polyethylene glycol 
PEI   Polyethylenimine 
PIE   Pulsed interleaved excitation 
PMSF   Phenylmethanesulfonyl fluoride 
PNPase  Polynucleotide phosphorylase 
PS   Phosphorothioate 
RISC   RNA induced silencing complex 
RNA   Ribonucleic acid 
RNAi   RNA interference 
Rnase  Ribonuclease 
RPMI medium Roswell Park Memorial Institute medium 
RT   Room temperature 
siRNA   Small interfering RNA 
ss   Single-stranded 
SS   Disulfide 
Stp   Succinoyl-tetraethylene pentamine 
TBE   Tris/borate/EDTA 
TCEP   Tris(2-carboxyethyl)phosphine 
TEMED  Tetramethylethylenediamine 
TMR   Tetramethylrhodamine 
UTR   Untranslated region 
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6.2. Additional methods 
 
6.2.1. Intensity FRET analysis 

For the intensity based FRET analysis, the FRET efficiency E was calculated 
according to equation S1: 
 
  	
			
	           (S1) 
 
where Ix denotes the fluorescence intensity in channel x. The individual channels 
were GG and GR for the green and red fluorescence after excitation with the 475 nm 
laser, respectively, and RR for the red signal after 565 nm excitation.  represents 
the direct excitation of tetramethylrhodamine at 475 nm excitation and  stands for 
the spectral cross-talk of Atto488 into the red channel. Using single dye controls, 
these values were determined to be 7.4 % for  and 13 % for  for the setup and 
measurement parameters used for this manuscript. , the parameter accounting for 
the different detection efficiency in the green and the red channels, could not be 
determined for the setup and was assumed to be equal to unity. However, varying 
the parameter within a reasonable range showed no significant effect on the 
measured degradation times. The FRET efficiency was calculated in 5 min intervals 
for the first hour and subsequently in 10 min intervals. The data was normalized to 
the initial data point. 
 
6.2.2. Lifetime FRET analysis 

For analyzing fluorescence lifetime based FRET, the phasor approach was used 
[113, 114]. Calculations were performed using the home written software package 
PAM. Here, each 10 min of the signal in the green channel was divided into 2500 
individual segments and, for each segment, the phasor coordinates were calculated. 
To account for the instrument response function, the data were referenced using an 
Atto488 carboxylic acid solution. The division into 2500 was done in order to be able 
to remove the influence of bright aggregates on the measured fluorescence lifetime. 
"##$

In order to be able to extract the fraction of molecules from the phasor positions, a 
simple two-component system was assumed. The first component consists of intact 
RNA exhibiting FRET and therefore a reduced fluorescence lifetime for the donor 
molecule, while the degraded RNA fragments constitute the second species showing 
no FRET signal and a longer fluorescence lifetime. During the experiment, ongoing 
degradation changes the ratio between the two components but the individual 
lifetimes stay the same. In the phasor plot, such a shift in fraction results in a straight 
line connecting the two base components. The relative contribution of the individual 
species can then be extracted from the exact position on this line. 
In practice, the lifetimes of both the intact and degraded species were not known a 
priori. To get these values, a line was extrapolated from the trajectory of the phasor 
coordinates during the measurement. The two intersects of this line with the universal 
circle were assumed to be the phasors of the base components. The lifetimes 
associated with these components varied slightly between the different species, but 
were generally around 1.2 ns for the cleaved species and 3.5 ns for the intact 
species. The later corresponds well to the lifetime measured for the control with just 
the donor fluorophore.  From the center position of the 2500 segments, the relative 
photon contribution of these components was calculated. Finally, this photon 
contribution was further corrected for the reduced brightness of the intact species due 
to FRET resulting in the fraction of intact RNA. The relative brightness was estimated 
from the ratio of the fluorescence lifetime.  
 
6.2.3. FCS and FCCS analysis 

The auto- and cross correlation curves were calculated from the photon traces using 
the software package PAM. In the first hour of the measurement, correlation curves 
were calculated for every 5 min, afterwards for every 10 min.  
The auto-correlations were fit with a two-component free diffusion model, assuming a 
3D Gaussian shape: 
       	   	    ! 	  "#$%&
   	 ' ()*+,- .,)*+,	/- .01	,)*+, 
21	(3456- .,3456	/- .01	,3456
7 8                    (S2)             
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Here, T and tT denote the dark state fraction and correlation time, respectively. Ni 
represents the average number of molecules in the focus for the slow or the fast 
component, while ti denotes their diffusion times.  is the shape factor of a 3D 
Gaussian profile and corresponds to 0.35355. The parameter p is the ratio between 
the axial and lateral focus size. To relate the amplitudes of the two components into 
number of molecules, the difference in molecular brightness of the two species has to 
be taken into account. Thus, the relative brightness  caused by quenching of the 
intact construct due to FRET needs to be used. It is estimated as the ratio of the 
lifetimes of the quenched and the unquenched states as given by the lifetime FRET 
analysis mentioned above. 
The slow component was assumed to represent the intact construct, while the fast 
component corresponds to the degraded fragments. Based on the Ni, the fraction of 
intact RNA was calculated for the green channel (GG) and the red channel after 
565 nm excitation (RR). 
The cross-correlation curves were fit with a simplified model using only a single 
component and no dark state term: 
 
  (99 	 -:-.,;	/- .01	,  8       (S3) 
 
Based on the Ni from the auto- and cross-correlation functions, the fraction of intact 
RNA was calculated according to: 
 
< "#$  /=(>*+,?(+456?@	=(>*+,?(+456?@2	(99     (S4) 
 
The parameter  again corrects for the decreased brightness of the intact species. 
 
6.2.4. FLIM analysis 

The phasor analysis for experiments on fixed cells was done in much the same way 
as for the lifetime based FRET measurements in cellular extracts. Pixels with 
intensities below a threshold of 200 photons were omitted from further analysis, thus 
eliminating the influence of the regions around the cells and limiting the influence of 
"##$
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auto-fluorescence. An upper threshold of 1000-2000 photons was also applied to 
remove RNA aggregates from the analysis. As described above, a line connecting 
the phasors of the degraded and the intact species was extrapolated. A histogram 
was generated from the positions of the individual pixel along that line (Figure 38a-d) 
that was subsequently fit with a Gaussian curve to extract the average lifetime 
(Figure 38e). 
 
 
6.3. Appendix figures 
 
 
Appendix Figure 1. Reproduction of the luciferase knockdown experiments at a constant N/P 
ratio of 6 with oligomer 689. The (a) star-shaped structures, the (b) substructures of 1bb2si, the (c) 
step-by-step extended structures and the (d) bioreducible structures were transfected with oligomer 
689 at a constant N/P ratio of 6. 
"##$
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Appendix Figure 2. Reproduction of the luciferase knockdown experiments at a constant N/P 
ratio with oligomer 356. The effect of INF7 on transfection efficiency was examined at a constant N/P 
ratio of 6, 12 and 24. 
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